<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7356537</article-id><article-id pub-id-type="doi">10.3390/jcm9061683</article-id><article-id pub-id-type="publisher-id">jcm-09-01683</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0720-3380</contrib-id><name><surname>Schiavone</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="af1-jcm-09-01683">1</xref><xref ref-type="aff" rid="af2-jcm-09-01683">2</xref><xref ref-type="author-notes" rid="fn1-jcm-09-01683">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Gobbi</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="af2-jcm-09-01683">2</xref><xref ref-type="author-notes" rid="fn1-jcm-09-01683">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Biondi-Zoccai</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="af3-jcm-09-01683">3</xref><xref ref-type="aff" rid="af4-jcm-09-01683">4</xref></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Ascenzo</surname><given-names>Fabrizio</given-names></name><xref ref-type="aff" rid="af5-jcm-09-01683">5</xref></contrib><contrib contrib-type="author"><name><surname>Palazzuoli</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="af6-jcm-09-01683">6</xref></contrib><contrib contrib-type="author"><name><surname>Gasperetti</surname><given-names>Alessio</given-names></name><xref ref-type="aff" rid="af1-jcm-09-01683">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3774-0104</contrib-id><name><surname>Mitacchione</surname><given-names>Gianfranco</given-names></name><xref ref-type="aff" rid="af1-jcm-09-01683">1</xref></contrib><contrib contrib-type="author"><name><surname>Viecca</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="af1-jcm-09-01683">1</xref></contrib><contrib contrib-type="author"><name><surname>Galli</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="af7-jcm-09-01683">7</xref><xref ref-type="aff" rid="af8-jcm-09-01683">8</xref></contrib><contrib contrib-type="author"><name><surname>Fedele</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="af9-jcm-09-01683">9</xref></contrib><contrib contrib-type="author"><name><surname>Mancone</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="af9-jcm-09-01683">9</xref><xref rid="c1-jcm-09-01683" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8895-8915</contrib-id><name><surname>Forleo</surname><given-names>Giovanni Battista</given-names></name><xref ref-type="aff" rid="af1-jcm-09-01683">1</xref><xref ref-type="aff" rid="af2-jcm-09-01683">2</xref></contrib></contrib-group><aff id="af1-jcm-09-01683"><label>1</label>Department of Cardiology, ASST-Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy; <email>marco.schiavone@unimi.it</email> (M.S.); <email>alessio.gasperetti93@gmail.com</email> (A.G.); <email>mitacchione.gianfra@asst-fbf-sacco.it</email> (G.M.); <email>viecca.maurizio@asst-fbf-sacco.it</email> (M.V.); <email>giovanni.forleo@unimi.it</email> (G.B.F.)</aff><aff id="af2-jcm-09-01683"><label>2</label>University of Milan, 20122 Milan, Italy; <email>cecilia.gobbi@unimi.it</email></aff><aff id="af3-jcm-09-01683"><label>3</label>Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy; <email>giuseppe.biondizoccai@uniroma1.it</email></aff><aff id="af4-jcm-09-01683"><label>4</label>Mediterranea Cardiocentro, 80122 Naples, Italy</aff><aff id="af5-jcm-09-01683"><label>5</label>Department of Medical Sciences, Division of Cardiology, AOU Citt&#x000e0; della Salute e della Scienza, University of Turin, 10126 Turin, Italy; <email>fabrizio.dascenzo@gmail.com</email></aff><aff id="af6-jcm-09-01683"><label>6</label>Cardiovascular Diseases Unit, Department of Medical Sciences, AOUS Le Scotte Hospital, University of Siena, 53100 Siena, Italy; <email>palazzuoli2@unisi.it</email></aff><aff id="af7-jcm-09-01683"><label>7</label>Department of Infectious Diseases, ASST-Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy; <email>massimo.galli@unimi.it</email></aff><aff id="af8-jcm-09-01683"><label>8</label>Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, 20157 Milan, Italy</aff><aff id="af9-jcm-09-01683"><label>9</label>Department of Clinical Internal, Anesthesiological and Cardiovascular Science, Sapienza University of Rome, 00161 Rome, Italy; <email>francesco.fedele@uniroma1.it</email></aff><author-notes><corresp id="c1-jcm-09-01683"><label>*</label>Correspondence: <email>massimomancone@gmail.com</email>; Tex.: +39-339-2454136; Fax: +39-06-49979047</corresp><fn id="fn1-jcm-09-01683"><label>&#x02020;</label><p>These authors contributed equally to this manuscript.</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2020</year></pub-date><volume>9</volume><issue>6</issue><elocation-id>1683</elocation-id><history><date date-type="received"><day>06</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>25</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Since an association between myocardial infarction (MI) and respiratory infections has been described for influenza viruses and other respiratory viral agents, understanding possible physiopathological links between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and acute coronary syndromes (ACS) is of the greatest importance. The initial data suggest an underestimation of ACS cases all over the world, but acute MI still represents a major cause of morbidity and mortality worldwide and should not be overshadowed during the coronavirus disease (Covid-19) pandemic. No common consensus regarding the most adequate healthcare management policy for ACS is currently available. Indeed, important differences have been reported between the measures employed to treat ACS in China during the first disease outbreak and what currently represents clinical practice across Europe and the USA. This review aims to discuss the pathophysiological links between MI, respiratory infections, and Covid-19; epidemiological data related to ACS at the time of the Covid-19 pandemic; and learnings that have emerged so far from several catheterization labs and coronary care units all over the world, in order to shed some light on the current strategies for optimal management of ACS patients with confirmed or suspected SARS-CoV-2 infection. </p></abstract><kwd-group><kwd>acute coronary syndromes</kwd><kwd>myocardial infarction</kwd><kwd>STEMI</kwd><kwd>Covid-19</kwd><kwd>infectious disease</kwd><kwd>respiratory infections</kwd><kwd>pathophysiology</kwd><kwd>percutaneous coronary intervention</kwd><kwd>thrombolysis</kwd><kwd>drug treatment</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-09-01683"><title>1. Introduction</title><p>In December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, Hubei province, spreading rapidly first throughout China, and subsequently across Europe, the United States (US), and the rest of the world [<xref rid="B1-jcm-09-01683" ref-type="bibr">1</xref>,<xref rid="B2-jcm-09-01683" ref-type="bibr">2</xref>,<xref rid="B3-jcm-09-01683" ref-type="bibr">3</xref>], reaching a total number of 3,435,894 confirmed cases worldwide as of 5 May 2020 [<xref rid="B4-jcm-09-01683" ref-type="bibr">4</xref>]. On 30 January 2020, the World Health Organization (WHO) declared the Covid-19 outbreak a public health emergency of international concern, and on 12 March -2020, it was characterized as a pandemic. Patients exposed to this virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), frequently present with fever, cough, and shortness of breath within 2 to 14 days after exposure, and then usually develop coronavirus disease (Covid-19)-related pneumonia [<xref rid="B5-jcm-09-01683" ref-type="bibr">5</xref>]. Although respiratory symptoms prevail among all clinical manifestations of Covid-19, preliminary studies showed that some patients may develop severe cardiovascular (CV) damage, while other patients with underlying CV diseases might have an increased risk of death [<xref rid="B5-jcm-09-01683" ref-type="bibr">5</xref>,<xref rid="B6-jcm-09-01683" ref-type="bibr">6</xref>,<xref rid="B7-jcm-09-01683" ref-type="bibr">7</xref>]. </p><p>Moreover, the Covid-19 outbreak has put a lot of pressure on overloaded healthcare systems, especially in Lombardy (Italy) and more generally in Northern Italy, where Covid-19 has spread very rapidly, causing concern regarding the capacity of the system to respond to the needs of intensive care treatments [<xref rid="B8-jcm-09-01683" ref-type="bibr">8</xref>]. All possible efforts have been made in order to give the maximum number of patients the chance to be admitted and treated in hospitals. All non-urgent procedures have been cancelled and routine clinical practice has been completely modified. In the context of an overwhelmed healthcare system, screening and elective treatments of coronary artery disease (CAD) have been underestimated, meaning dealing with acute coronary syndromes (ACS) has become more complicated and apparently less frequent. Nevertheless, ACS still remain a major cause of morbidity and mortality worldwide and are responsible for more than 1 million hospital admissions in the US annually, while ischemic heart disease accounts for almost 1.8 million annual deaths, or 20% of all deaths in Europe, although with large variations between different European countries [<xref rid="B9-jcm-09-01683" ref-type="bibr">9</xref>,<xref rid="B10-jcm-09-01683" ref-type="bibr">10</xref>].</p><p>During this pandemic, links between SARS-CoV-2 and ACS have not been established yet and a common guidance on how to handle ACS in Covid-19 and non-Covid-19 patients is needed. The aim of this review is to shed some light on those issues, analyzing possible physiopathological links between Covid-19 and ACS and evaluating the best strategy to balance optimal ACS management and infectious risks related to Covid-19 outbreak.</p></sec><sec id="sec2-jcm-09-01683"><title>2. Acute Coronary Syndromes and COVID-19</title><sec id="sec2dot1-jcm-09-01683"><title>2.1. Pathophysiology </title><p>Acute coronary syndromes (ACS) reflect a spectrum of pathological conditions compatible with acute myocardial ischemia or infarction that are usually due to an abrupt reduction in coronary blood flow [<xref rid="B11-jcm-09-01683" ref-type="bibr">11</xref>]. The clinical spectrum of ACS may range from myocardial infarction with ST-segment elevation (STEMI), which generally reflects an acute total coronary occlusion, to myocardial infarction without ST-segment elevation (NSTEMI) or unstable angina (UA), with or without myocardial injury, respectively [<xref rid="B12-jcm-09-01683" ref-type="bibr">12</xref>]. The current fourth universal definition defines myocardial infarction (MI) as the presence of acute myocardial injury, detected by an elevated cardiac troponin (cTn) value above the 99th percentile of the upper reference limit (URL), in the setting of evidence of acute myocardial ischemia related to symptoms, electrocardiogram (ECG), imaging changes, or angiographic findings [<xref rid="B13-jcm-09-01683" ref-type="bibr">13</xref>]. Furthermore, cTn I and T, regulatory components of the contractile apparatus of myocardial cells, are the preferred biomarkers for the evaluation of myocardial injury and have been used worldwide. It should be underlined that any type of myocardial injury can result in significant cTn release into the blood, but cTn elevation does not allow for discrimination between the underlying pathophysiological mechanisms [<xref rid="B14-jcm-09-01683" ref-type="bibr">14</xref>]. Several clinical conditions related to the mismatch between oxygen supply and demand, such as respiratory failure (predominantly hypoxaemia) and infectious disease (particularly sepsis), may induce or lead to myocardial injury or to type 2 MI [<xref rid="B13-jcm-09-01683" ref-type="bibr">13</xref>,<xref rid="B15-jcm-09-01683" ref-type="bibr">15</xref>,<xref rid="B16-jcm-09-01683" ref-type="bibr">16</xref>]. Mechanisms related to myocardial injury are summarized in <xref rid="jcm-09-01683-t001" ref-type="table">Table 1</xref>. </p><p>Identification of type 2 MI can be challenging due to more frequent atypical clinical presentations (such as with dyspnoea), higher prevalence of comorbidities that may mask ischemia [<xref rid="B17-jcm-09-01683" ref-type="bibr">17</xref>], and lower frequency of ischemic electrocardiographic findings (Q waves or new ST-T wave changes) and new regional wall motion abnormalities. Moreover, culprit lesions can be identified in a small percentage of cases by coronary angiography [<xref rid="B18-jcm-09-01683" ref-type="bibr">18</xref>,<xref rid="B19-jcm-09-01683" ref-type="bibr">19</xref>,<xref rid="B20-jcm-09-01683" ref-type="bibr">20</xref>,<xref rid="B21-jcm-09-01683" ref-type="bibr">21</xref>]. Nowadays, it is well accepted that sepsis and other infections are associated with CV events, especially ACS [<xref rid="B22-jcm-09-01683" ref-type="bibr">22</xref>,<xref rid="B23-jcm-09-01683" ref-type="bibr">23</xref>]. In particular, the risk of MI in the context of respiratory infectious disease reaches a peak at the onset of infections and is proportional to the severity of illness [<xref rid="B22-jcm-09-01683" ref-type="bibr">22</xref>]. Acute respiratory failure with consequent severe hypoxaemia contributes to reduce oxygen supply and determines activation of the sympathetic system, which increases heart rate, cardiac output, and contractility, factors that can increase myocardial oxygen demand [<xref rid="B24-jcm-09-01683" ref-type="bibr">24</xref>,<xref rid="B25-jcm-09-01683" ref-type="bibr">25</xref>]. Incidence of myocardial injury or infarction in critically ill patients may go unrecognized [<xref rid="B26-jcm-09-01683" ref-type="bibr">26</xref>], as post-mortem studies have suggested, where a prevalence of undiagnosed acute myocardial infarction (AMI) ranging from 5% to 25% in patients who died from acute respiratory failure was observed [<xref rid="B27-jcm-09-01683" ref-type="bibr">27</xref>,<xref rid="B28-jcm-09-01683" ref-type="bibr">28</xref>]. </p><p>Another possible mechanism implicated in the association between respiratory tract infections and ACS is the pro-inflammatory state. Since this association has been established for a variety of pathogens and sites of infection, it is likely that the causal agent and the host response could have a crucial role in eliciting an inflammatory pattern that may trigger ACS [<xref rid="B22-jcm-09-01683" ref-type="bibr">22</xref>]. Atherosclerotic plaques contain inflammatory cells that proliferate and secrete cytokines that stimulate smooth muscle cells to form a fibrous cap [<xref rid="B29-jcm-09-01683" ref-type="bibr">29</xref>]. An inflammatory state at any other site generates circulating cytokines, such as interleukins 1, 6, and 8 and tumor necrosis factor &#x003b1;, which can activate inflammatory cells in atherosclerotic plaques [<xref rid="B30-jcm-09-01683" ref-type="bibr">30</xref>]. Studies in murine models [<xref rid="B31-jcm-09-01683" ref-type="bibr">31</xref>] and post-mortem studies in humans [<xref rid="B32-jcm-09-01683" ref-type="bibr">32</xref>] have shown that inflammatory activity in atheromatous plaques increases after an infectious stimulus. When activated, intraplaque inflammatory cells, especially macrophages and T-cells, upregulate host response proteins, including metalloproteinases and peptidases, which degrade components of the extracellular matrix and promote an oxidative burst, all of which contribute to destabilization of plaques [<xref rid="B33-jcm-09-01683" ref-type="bibr">33</xref>,<xref rid="B34-jcm-09-01683" ref-type="bibr">34</xref>]. When the plaque surface becomes disrupted, thrombogenic elements (collagen, phospholipids, tissue factor, and platelet-adhesive matrix molecules) are exposed, leading to the acute formation of a thrombus, which is the typical mechanism related to type 1 MI [<xref rid="B35-jcm-09-01683" ref-type="bibr">35</xref>]. Moreover, inflammation promotes a prothrombotic state, which could further increase the risk of microangiopathy in multiple organs [<xref rid="B36-jcm-09-01683" ref-type="bibr">36</xref>] and coronary thrombosis at sites of plaque disruption [<xref rid="B37-jcm-09-01683" ref-type="bibr">37</xref>]. The inflammatory reaction in the coronary arteries impairs fibrinolysis through the inhibition of action of antithrombin, protein C system, and tissue factor pathway inhibitor, three major coagulation-inhibiting proteins that facilitate thrombosis [<xref rid="B38-jcm-09-01683" ref-type="bibr">38</xref>,<xref rid="B39-jcm-09-01683" ref-type="bibr">39</xref>]. Finally, influenza viruses and other viral respiratory infections are associated with expression of genes that have been linked to platelet activation and to an increased risk of MI [<xref rid="B40-jcm-09-01683" ref-type="bibr">40</xref>].</p></sec><sec id="sec2dot2-jcm-09-01683"><title>2.2. ACS and Other Acute Respiratory Infections </title><p>In the early 20th century, an excess mortality during influenza and pneumonia epidemics was first recognized [<xref rid="B41-jcm-09-01683" ref-type="bibr">41</xref>], but the specific association with influenza or other respiratory infections and MI was not described until decades later (see <xref rid="jcm-09-01683-t002" ref-type="table">Table 2</xref>). </p><p>More recent studies have documented an increased risk of MI with influenza, pneumonia, acute bronchitis, and other chest infections [<xref rid="B42-jcm-09-01683" ref-type="bibr">42</xref>,<xref rid="B43-jcm-09-01683" ref-type="bibr">43</xref>,<xref rid="B44-jcm-09-01683" ref-type="bibr">44</xref>]. In retrospective and prospective case series, a rate of CV events of about 30% and a rate of MI of about 8% were found among patients who were hospitalized for community-acquired pneumonia [<xref rid="B45-jcm-09-01683" ref-type="bibr">45</xref>,<xref rid="B46-jcm-09-01683" ref-type="bibr">46</xref>]. Other retrospective studies suggested that hospitalization for pneumonia was associated with both short and long-term increased risk of CV events; in an analysis performed by Medina et al., 318 out of 1271 patients (25%) developed CV events over 10 years after pneumonia hospitalization [<xref rid="B47-jcm-09-01683" ref-type="bibr">47</xref>]. A meta-analysis of 10 case&#x02013;control studies conducted by Barnes et al. demonstrated a two-fold increased risk of AMI in patients with recent influenza infection or respiratory tract infection; a recent influenza infection, influenza-like illness, or other respiratory tract infection was significantly more likely in AMI cases, with a pooled odds ratio (OR) of 2.01 (95% confidence interval CI: 1.47 to 2.76) [<xref rid="B53-jcm-09-01683" ref-type="bibr">53</xref>]. From a large American database, among 1, 884, 985 admissions for AMI from January 2013 to December 2014, influenza or other viral respiratory infections accounted for 1.1% of the patients (9885 and 11485 patients respectively) and were associated with worse outcomes and higher in-hospital case fatality (approximately 13%) [<xref rid="B48-jcm-09-01683" ref-type="bibr">48</xref>]. </p><p>Vejpongsa et al. also showed that AMI patients with concomitant influenza infection or other viral respiratory infections were less likely to receive cardiac catheterization across all age groups when compared with patients with AMI alone (22% vs. 43.8% vs. 58.8%, <italic>p</italic> &#x0003c; 0.001) [<xref rid="B48-jcm-09-01683" ref-type="bibr">48</xref>]. However, amongst those patients who underwent coronary catheterization in the three different groups, more than half required revascularization; the rate of revascularization was lower in those with concomitant influenza than those without, suggesting that clinicians had appropriately identified which patients should undergo coronary angiography [<xref rid="B48-jcm-09-01683" ref-type="bibr">48</xref>]. These interesting findings should be highlighted and related to what is currently happening during this Covid-19 pandemic, given that patients infected with SARS-CoV-2 virus seem to undergo cardiac catheterization less, likely due to high risk of infection spreading.</p><p>Two other studies have evaluated the prevalence of respiratory infections and influenza among patients with angiographically confirmed MI [<xref rid="B49-jcm-09-01683" ref-type="bibr">49</xref>] and STEMI [<xref rid="B50-jcm-09-01683" ref-type="bibr">50</xref>], respectively. Ruane et al. confirmed that respiratory infections can trigger MI [<xref rid="B50-jcm-09-01683" ref-type="bibr">50</xref>] and Caussin et al. showed that influenza epidemic may be associated with a significant excess relative risk of STEMI [<xref rid="B49-jcm-09-01683" ref-type="bibr">49</xref>]. These results have to be underlined, since these authors only analyzed cases with angiographically confirmed MI, limiting the potential bias of other studies based on retrospective database analysis related to the inclusion of cases with myocardial injury (potentially misdiagnosed as MI), especially considering the association between cTn elevation and sepsis.</p><p>Acute coronary syndromes and MI were also noted to occur in severe acute respiratory syndrome (SARS), an infectious disease that afflicted a total of 8096 people in 29 countries in 2003, with a mortality around 9.6% [<xref rid="B54-jcm-09-01683" ref-type="bibr">54</xref>]. In a prospective study of 75 patients hospitalized with SARS, AMI was the cause of death in 2 out of 5 fatal cases [<xref rid="B51-jcm-09-01683" ref-type="bibr">51</xref>]. A study from Singapore reported post-mortem examinations in 8 patients who died suddenly and unexpectedly from SARS; 1 out of 8 patient had subendocardial infarction with occlusive coronary disease (as well as AMI on presentation with SARS), while 4 patients had pulmonary thromboembolism and 1 patient developed marantic valvular vegetations, along with infarction in the heart, kidneys, spleen, and brain [<xref rid="B52-jcm-09-01683" ref-type="bibr">52</xref>]. These findings suggest a possible link between severe acute respiratory syndromes, thrombophilia, and subsequently ACS. Additionally, Middle East respiratory syndrome (MERS), which was first reported in 2012 in Saudi Arabia and has afflicted 2519 patients with 866 associated deaths (case-fatality rate: 34.4%) in 27 countries [<xref rid="B55-jcm-09-01683" ref-type="bibr">55</xref>], has been related to CV diseases. A systematic analysis of 637 MERS patients showed that 30% of cases had underlying cardiac diseases, 50% had hypertension, 50% had diabetes, and 16% had obesity [<xref rid="B56-jcm-09-01683" ref-type="bibr">56</xref>]. The clinical risk factors for mortality in MERS were older age, male sex, and CV-related underlying medical conditions, including hypertension, diabetes, cardiac diseases, and chronic kidney disease [<xref rid="B57-jcm-09-01683" ref-type="bibr">57</xref>,<xref rid="B58-jcm-09-01683" ref-type="bibr">58</xref>,<xref rid="B59-jcm-09-01683" ref-type="bibr">59</xref>]. Data on the incidence of ACS in the context of MERS infection are lacking. Alhogbani reported a case of a 60-year-old patient with MERS coronavirus (MERS-CoV) infection who presented with respiratory symptoms, chest pain, TnT elevation, diffuse T-wave inversion, and severe left ventricular (LV) dysfunction; acute myocarditis was then diagnosed with cardiac magnetic resonance, which excluded an ischemic cardiomyopathy [<xref rid="B60-jcm-09-01683" ref-type="bibr">60</xref>]. </p><p>A different relative risk of MI with several respiratory infections has been described by Kwong et al. [<xref rid="B43-jcm-09-01683" ref-type="bibr">43</xref>]. Incidence ratios for AMI within 7 days after detection of influenza B, influenza A, respiratory syncytial virus, and other viruses were 10.11 (95% CI, 4.37 to 23.38), 5.17 (95% CI, 3.02 to 8.84), 3.51 (95% CI, 1.11 to 11.12), and 2.77 (95% CI, 1.23 to 6.24), respectively. Additionally, Guan et al. analyzed the potential relationship between AMI and previous influenza virus infection, and found that AMI was associated with the presence of IgG antibodies to influenza virus A, B, herpes simplex virus 1 and 2 (HSV1-2), cytomegalovirus (CMV), HSV-1 and HSV-2, adenovirus (ADV), rhinovirus (RV), and chlamydia pneumonia with different OR (in particular, adjusted OR for influenza A 5.5, 95% CI: 1.3&#x02013;23.0; adjusted OR for influenza B: 20.3, 95% CI: 5.6&#x02013;40.8) [<xref rid="B61-jcm-09-01683" ref-type="bibr">61</xref>]. Those findings suggest a stronger correlation between influenza B virus infection and AMI; however, evidence on the mechanisms that may lead to different AMI rates in relationship with some viral infections are lacking. Limitations regarding laboratory testing, baseline characteristics (comorbidities and vaccinations), and clinical courses of the infections (mild or severe) may affect the estimation of the absolute risk of AMI during or after different viral infections.</p><p>Moreover, the pooled results of the aforementioned meta-analysis from Barnes et al. demonstrated an association between influenza vaccination and a lower risk of composite CV events, with a pooled OR of 0.71 (95% CI: 0.56 to 0.91), equating to an estimated vaccine effectiveness of 29% (95% CI: 9% to 44%) against AMI [<xref rid="B53-jcm-09-01683" ref-type="bibr">53</xref>]. This finding is in line with other results from another meta-analysis from Udell et al., which showed that the influenza vaccine given to high-risk patients, such as patients with CAD, reduced their risk of a major adverse cardiovascular event (MACE) (patients treated with influenza vaccine and MACE (2.9%) vs. patients treated with placebo or control and MACE (4.7%); RR, 0.64 (95% CI: 0.48&#x02013;0.86), <italic>p</italic> = 0.003) [<xref rid="B62-jcm-09-01683" ref-type="bibr">62</xref>]. Therefore, current European guidelines on the diagnosis and management of chronic coronary syndromes recommend annual influenza vaccination in order to improve prevention of AMI in patients with CAD and decrease CV mortality [<xref rid="B63-jcm-09-01683" ref-type="bibr">63</xref>,<xref rid="B64-jcm-09-01683" ref-type="bibr">64</xref>,<xref rid="B65-jcm-09-01683" ref-type="bibr">65</xref>].</p></sec><sec id="sec2dot3-jcm-09-01683"><title>2.3. Myocardial Injury and ACS in Patients with Covid-19: What We Know</title><p>Although the clinical manifestations of Covid-19 are dominated by respiratory symptoms, evidence of myocardial injury was recognized in early cases in China (see <xref rid="jcm-09-01683-t003" ref-type="table">Table 3</xref>).</p><p>Huang et al. first reported a prevalence of acute myocardial injury of 12% as a major complication among 41 hospitalized patients infected with SARS-CoV-2 [<xref rid="B5-jcm-09-01683" ref-type="bibr">5</xref>]. In another study from Wang et al. conducted on 138 hospitalized patients with Covid-19, cardiac injury was found in 7.2% of patients overall and in 22.2% of patients who were treated in the intensive care unit (ICU) [<xref rid="B1-jcm-09-01683" ref-type="bibr">1</xref>]. These findings could suggest that acute myocardial injury may have a relevant role in worsening clinical outcomes in Covid-19 patients, even without clear evidence of myocardial ischemia. Indeed, Zhou et al., in a retrospective report of 191 patients admitted with SARS-Cov-2 pneumonia, diagnosed acute myocardial injury in 33 out of 191 (17%) patients in their cohort [<xref rid="B66-jcm-09-01683" ref-type="bibr">66</xref>]. Interestingly, they found that non-survivors were more likely to develop acute myocardial injury than survivors (<italic>n</italic> = 32, 59% vs. <italic>n</italic> = 1, 1%; <italic>p</italic> &#x0003c; 0.0001). Notably, the first autopsy in this cohort was performed on a 53-year-old woman with chronic renal failure, and findings were consistent with AMI (data resulting from personal communication between a pathologist and the Chinese Academy of Science, not available in a published manuscript). In a single-center retrospective study by Shi et al., conducted on a cohort of 416 consecutive Covid-19 patients in Wuhan, China, cardiac injury was found in 19.7% patients (<italic>n</italic> = 82) [<xref rid="B6-jcm-09-01683" ref-type="bibr">6</xref>]. Those patients were older, had more CV comorbidities (hypertension, diabetes, cerebrovascular disease, and heart failure), and presented with more severe acute illness than patients without cardiac injury. This study demonstrated that myocardial injury was independently associated with an increased risk of mortality in patients with Covid-19. It should be underlined that among those 82 patients with cardiac injury, only 22 (26.8%) underwent an electrocardiogram (ECG) after admission, and only 14 out of 22 ECGs (63.6%) were performed at the same time as the elevation of cardiac biomarkers. All ECGs were described as abnormal, with findings compatible with myocardial ischemia, such as T-wave depression and inversion, ST-segment depression, and Q waves. The above findings may suggest that 14 out of 416 patients in this cohort (3.36%) may have developed myocardial ischemia, with features consistent with NSTEMI. No evidence of STEMI in this cohort was provided, even if limited availability of ECGs may have led to underestimation of AMI cases. In addition, the National Health Commission of China reported that among people who died from Covid-19, 11.8% of patients without underlying CV diseases had substantial heart damage, showing elevated levels of cTnI or cardiac arrest during hospitalization [<xref rid="B67-jcm-09-01683" ref-type="bibr">67</xref>]. In a meta-analysis by Lippi et al. that included a total number of 341 patients (123 with severe disease, 36%), it appeared that cTnI values were significantly increased in patients with severe SARS-CoV-2 infection compared to those with milder forms of disease [<xref rid="B68-jcm-09-01683" ref-type="bibr">68</xref>].</p><p>Several mechanisms that could explain the onset of acute myocardial injury related to myocardial ischemia in SARS-CoV-2 infection have been proposed. Some of them may resemble the ones identified for other respiratory infectious agents, such a pro-inflammatory state and a cytokine storm (which could cause plaque instability), or a prothrombotic state and hypoxaemia-related damage due to acute respiratory failure. The rise in cTn tracks with other inflammatory biomarkers, such as D-dimer, interleukin-6, and lactate dehydrogenase, raises the possibility that this may reflect cytokine storm more than isolated myocardial injury [<xref rid="B69-jcm-09-01683" ref-type="bibr">69</xref>]. On the other hand, some reports of patients presenting with cardiac symptoms, ECG changes, or new wall motion abnormalities may suggest a different pattern, such as viral myocarditis and stress cardiomyopathy. The underutilization of coronary angiography during this outbreak due to the high infectious risk makes it more difficult to establish a definite differential diagnosis in many cases.</p><p>Furthermore, specific damage caused by SARS-CoV-2 infection might be related to angiotensin-converting enzyme 2 (ACE2) receptors, which have been shown to represent the entry point into human cells for some coronaviruses, such as SARS-CoV and SARS-CoV-2. ACE2 receptors are widely expressed in both the lungs and the CV system; therefore, ACE2- related signalling pathways might also have a role in myocardial injury. At the time of writing, a lot of studies are ongoing all over the world, which will hopefully tell us more about the link between ACE2 receptors, Covid-19, and CV diseases.</p></sec></sec><sec sec-type="subjects" id="sec3-jcm-09-01683"><title>3. Critical Issues in Management and Treatment of ACS Patients</title><sec id="sec3dot1-jcm-09-01683"><title>3.1. Where did All the STEMIs Go?</title><p>The relevant impact of Covid-19 pandemic is related to the diagnosis and management of patients with ACS who were not hospitalized for confirmed or suspected Covid-19. Diagnosis and treatment of ACS&#x02014;especially STEMI&#x02014;start from the point of first medical contact (FMC), defined as the time point when the patient is initially assessed by a physician, paramedic, nurse, or trained medical personnel who can interpret the ECG and deliver medical interventions in the pre-hospital or in-hospital setting [<xref rid="B70-jcm-09-01683" ref-type="bibr">70</xref>]. Prompt activation of emergency medical services (EMS) is crucial, since ischemic time duration is a major determinant of infarct size in patients with STEMI, while prompt recognition and early management are critical in reducing morbidity and mortality related to ACS [<xref rid="B71-jcm-09-01683" ref-type="bibr">71</xref>]. It has been postulated that in the midst of this healthcare crisis, hospital admissions for ACS have dramatically decreased, mostly due to the fact that patients do not activate EMS because of the &#x0201c;do not come to the hospital&#x0201d; policy and due the fact that hospitals are now perceived as dangerous places. Prof. B. Casadei, Professor of Cardiovascular Medicine at the University of Oxford and European Society of Cardiology (ESC) president, stated that in the worst hit areas, hospital admissions for ACS were reduced by up to 75% [<xref rid="B72-jcm-09-01683" ref-type="bibr">72</xref>]. In the US and Spain, approximately 38% and 40% reductions in cardiac catheterization laboratory STEMI activations were experienced [<xref rid="B73-jcm-09-01683" ref-type="bibr">73</xref>,<xref rid="B74-jcm-09-01683" ref-type="bibr">74</xref>], respectively, while in Italy a reduction in hospitalizations for STEMI (26.5%; less striking than with NSTEMI&#x02014;65.1%) was reported [<xref rid="B75-jcm-09-01683" ref-type="bibr">75</xref>]. Those findings were corroborated by De Filippo et al., who performed a retrospective analysis on consecutive patients who were admitted at 15 hospitals in northern Italy for ACS. They showed that the mean admission rate for ACS during the study period (20 February 2020, to 31 March 2020) was 13.3 admissions per day vs. 18.0 admissions per day during the earlier period in the same year vs. 18.9 admissions per day during the same timeframe of the previous year [<xref rid="B76-jcm-09-01683" ref-type="bibr">76</xref>]. </p></sec><sec id="sec3dot2-jcm-09-01683"><title>3.2. Are We Really Prioritizing and Treating STEMI Patients the Way We Should?</title><p>In Hong Kong, Tam et al. described a small number of patients with STEMI seeking medical help (<italic>n</italic> = 7) and found large delays in presentation after infection control measures were implemented in their country when compared to 2018&#x02013;2019 presentation times during office and non-office hours, respectively, where median symptom onset to first medical contact = 318 min (IQ range: 75&#x02013;448) vs. 82.5 min (IQ range: 32.5&#x02013;195) vs. 91.5 min (IQ range: 32.25&#x02013;232.75) [<xref rid="B77-jcm-09-01683" ref-type="bibr">77</xref>]. The reason proposed for these delays vary and are mostly related to hesitancy to go to the emergency department (ED) or to activate the EMS, introducing a first &#x0201c;Covid-19-related delay&#x0201d; in the so-called &#x0201c;total ischemia time&#x0201d; (<xref ref-type="fig" rid="jcm-09-01683-f001">Figure 1</xref>). </p><p>Tam et al. also postulated that many STEMI patients do not seek care at all, which may contribute to a global underestimation of ACS cases [<xref rid="B77-jcm-09-01683" ref-type="bibr">77</xref>]. In Italy&#x02014;particularly in Lombardy&#x02014;similarly to in several other European countries and US states, the healthcare system has also been facing a huge overload, causing unbearable consequences on resources for cardiology, since the availability of ward and cardiology care unit (CCU) beds have been drastically reduced and admissions for elective procedures have been suspended (such as coronary catheterizations). The EMS is now focused on dealing with the Covid-19 outbreak, so less resources are available to cope with other emergencies such as ACS, due to limited means of support and healthcare staff, who are either sick or committed to handling the Covid-19 emergency. In order to avoid SARS-CoV-2 spreading, on 8 March 2020, the government of Lombardy identified 13 hospitals with catheterization laboratories acting as <italic>&#x0201c;hubs&#x0201d;</italic>, with the remaining hospitals acting as <italic>&#x0201c;spokes&#x0201d;</italic>, in order to gather cardiovascular emergencies in certain coronary care units (CCUs) all across the region [<xref rid="B78-jcm-09-01683" ref-type="bibr">78</xref>]. About 10 million people live in Lombardy, representing one-sixth of the Italian population, meaning that this reorganization introduced another &#x0201c;Covid-19-related delay&#x0201d; (<xref ref-type="fig" rid="jcm-09-01683-f001">Figure 1</xref>) in managing patients with STEMI, who were potentially more distant from a <italic>&#x0201c;hub&#x0201d;</italic> catheterization laboratory when activating EMS. Moreover, <italic>&#x0201c;hubs&#x0201d;</italic> must have more than 1 catheterization lab, and at least 1 of those should be dedicated to suspected or diagnosed Covid-19 patients, so that the most appropriate protocol can be followed. Major impacts of this healthcare policy are expected, since delays in seeking and delivering care due to patient fears of contracting an infection from the healthcare system and longer times taken to reach <italic>&#x0201c;hubs&#x0201d;</italic> could have harmful impacts on ACS patients outcomes.</p><p>During this pandemic, finding a balance between risks related to untimely treatment of ACS patients and SARS-CoV-2 infection control has become a global challenge. Commonly, regional reperfusion strategies are established to maximize efficiency in treatments, since primary percutaneous coronary intervention (PCI)&#x02014;bypassing the ED&#x02014;is the routine treatment for STEMI patients [<xref rid="B79-jcm-09-01683" ref-type="bibr">79</xref>]. Several trials and meta-analyses endorsed by European and American Guidelines have clearly established the superiority of primary PCI compared to thrombolysis over the years. As early as 1997, a quantitative review published by Weaver et al. based on outcomes at hospital discharge or at 30 days demonstrated that primary PCI was superior to thrombolytic therapy for treatment of patients with AMI (<italic>n</italic> = 2606); mortality at 30 days or less was 4.4% for patients treated with primary PCI (<italic>n</italic> = 1290) compared with 6.5% for patients treated with thrombolysis (<italic>n</italic> = 1316), representing a 34% reduction (OR, 0.66; 95% CI, 0.46&#x02013;0.94; <italic>p</italic> = 0.02) [<xref rid="B80-jcm-09-01683" ref-type="bibr">80</xref>]. More recently, a pooled analysis of 22 randomized trials (total patients <italic>n</italic> = 6763) by Boersma et al. demonstrated that primary PCI was associated with significantly lower 30-day mortality rate compared to thrombolysis (adjusted OR, 0.63; 95% CI (0.42&#x02013;0.84)), regardless of treatment delay [<xref rid="B81-jcm-09-01683" ref-type="bibr">81</xref>].</p><p>Despite this clinical evidence, to cope with the abrupt Covid-19 outbreak, case decisions were individualized at the beginning of the pandemic, taking into account the risk of SARS-CoV-2 exposure versus the risk of delaying diagnosis or therapy. Subsequently, Peking Union Medical College Hospital and Sichuan Provincial People&#x02019;s Hospital proposed recommendations in China, which are summarized as follows [<xref rid="B82-jcm-09-01683" ref-type="bibr">82</xref>,<xref rid="B83-jcm-09-01683" ref-type="bibr">83</xref>]: with regard to STEMI patients, thrombolytic therapy was recommended over primary PCI if Covid-19 was confirmed or could not be excluded within a short time, while for NSTEMI&#x02013;UA, the priority was to exclude SARS-CoV-2 infection first, since door-to-balloon time is less crucial in those patients than in STEMIs. These recommendations were endorsed by Daniels et al., who stated that thrombolysis might be the best compromise of prompt reperfusion for the patient, buying time for a complete diagnosis to be made [<xref rid="B84-jcm-09-01683" ref-type="bibr">84</xref>]. According to Peking&#x02019;s protocol, blood tests, pharyngeal swab or sputum specimen, or blood samples should be performed for detection of SARS-CoV-2 nucleic acid before starting treatment, in addition to chest computed tomography (CT) scanning and evaluation by infectious disease specialists [<xref rid="B82-jcm-09-01683" ref-type="bibr">82</xref>]; while Sichuan&#x02019;s protocol relies on rapid nucleic acid testing before starting care. These recommendations are undoubtedly useful for minimizing and controlling the spread of SARS-CoV-2 infection, but data on the outcomes of ACS patients are needed to confirm that delaying treatment and use of thrombolysis as a first therapy to treat STEMI in confirmed or suspected Covid-19 patients are not associated with worse outcomes. </p><p>Indeed, despite Lombardy being considered an area with cluster transmission of SARS-CoV-2 since late February 2020, most <italic>&#x0201c;hubs&#x0201d;</italic> are performing primary PCI without waiting for screening test results in order to avoid important delays and reliance on thrombolysis. Stefanini et al. performed a retrospective analysis on 28 Covid-19 patients who were admitted for STEMI: they found that 24 patients (85.7%) did not have a SARS-CoV-2 test result at the time of coronary angiography and that 11 patients (39.3%) did not have obstructive CAD [<xref rid="B85-jcm-09-01683" ref-type="bibr">85</xref>]. In line with the aforementioned analysis, in our tertiary care center (&#x0201c;Ospedale Luigi Sacco&#x0201d;, Milan, Italy) located in the heart of the Italian epidemic, no cases of ACS requiring PCI were reported among more than 900 patients admitted for SARS-CoV-2 infection, as of May 5, 2020, suggesting a possible link between SARS-CoV-2 and type 2 MI or myocarditis&#x02013;stress cardiomyopathy. A case report from Hu et al. described a 37-years-old male patient presenting with chest pain and dyspnea, with ST-segment elevation in the inferior leads, elevation of TnT, and severe depression of LV ejection fraction (27%), in which an emergency coronary computed tomography angiography (CCTA) revealed no coronary stenosis and a diagnosis of fulminant myocarditis was made [<xref rid="B86-jcm-09-01683" ref-type="bibr">86</xref>]. Another case report from Inciardi et al. described a patient infected with SARS-CoV-2 that had severe fatigue, no chest pain, minimal diffuse ST-segment elevation (more prominent in the inferior and lateral leads), an ST-segment depression with T-wave inversion in lead V1 and aVR, severe LV dysfunction, and no evidence of obstructive CAD at time of urgent coronary angiography, who was then diagnosed with acute myopericarditis [<xref rid="B87-jcm-09-01683" ref-type="bibr">87</xref>]. A first case series from New York City (USA) described 18 Covid-19 patients with ST-segment elevation indicating potential AMI; among those patients, 9 (50%) underwent coronary angiography, 6 out of 9 (67%) had obstructive disease, and 5 (56%) underwent PCI [<xref rid="B88-jcm-09-01683" ref-type="bibr">88</xref>]. All these findings should be underlined by considering that in such cases, thrombolytic therapy&#x02014;if used&#x02014;may have increased the hemorrhagic risk without adding any benefit on the ischemic side. Since reperfusion seems not to be mandatory in a great number of patients (possibly due to the previously highlighted link between respiratory infections and type 2 MI), relying on systematic thrombolysis seem not to be justified from these initial European and American reports [<xref rid="B85-jcm-09-01683" ref-type="bibr">85</xref>,<xref rid="B88-jcm-09-01683" ref-type="bibr">88</xref>]. Hence, also based on those findings, the Society for Cardiovascular Angiography and Interventions (SCAI), American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), and American Heart Association (AHA) published guidance on the management of AMI during the Covid-19 pandemic in the US [<xref rid="B89-jcm-09-01683" ref-type="bibr">89</xref>,<xref rid="B90-jcm-09-01683" ref-type="bibr">90</xref>]. These guidelines state that after a first evaluation in the ED to assess the infectious risks, STEMI patients should undergo primary PCI whenever possible if it can be provided within an adequate time frame from the symptoms onset and STEMI diagnosis. STEMI patients should be transferred to the catheterization laboratory as rapidly as possible, and although door-to-balloon times are expected to be longer during the Covid-19 pandemic, a primary PCI strategy should remain the first choice. Thrombolytic therapy should not be the standard of care strategy and should be limited to particular situations, such as in non-PCI capable hospital or when PCI cannot be performed within an acceptable time frame. Those latest recommendations are more consistent with general European and American Guidelines on STEMI [<xref rid="B70-jcm-09-01683" ref-type="bibr">70</xref>,<xref rid="B91-jcm-09-01683" ref-type="bibr">91</xref>], confirming that primary PCI remains the reperfusion therapy of choice if feasible within an acceptable time frame from STEMI diagnosis. </p><p>In summary, protocols should guarantee the feasibility of performing PCI in facilities approved for treatment of Covid-19 patients, avoiding potentially harmful thrombolysis, in compliance with adequate safety measures to protect healthcare workers (see after), since primary PCI should remain the default strategy in patients with clear evidence of a STEMI, as clearly stated in American guidelines on the management of AMI during the Covid-19 pandemic [<xref rid="B89-jcm-09-01683" ref-type="bibr">89</xref>]. An efficacious strategy could be to organize separated catheterization labs and subsequently CCUs or cardiology wards for patients with and without SARS-CoV-2 infections, although this may be possible only in high volume hospitals. On 3 April 2020, SCAI and the Canadian Association of Interventional Cardiology (CAIC) announced the formation of the North American Covid-19 ST-Segment Elevation Myocardial Infarction Registry (NACMI) [<xref rid="B92-jcm-09-01683" ref-type="bibr">92</xref>], which hopefully will tell us more about this topic, since further data are needed to detect and characterize patients with STEMI and Covid-19 and to optimize treatment.</p></sec><sec id="sec3dot3-jcm-09-01683"><title>3.3. Organization Issues for Workers and Catheterization Labs</title><p>Catheterization lab staff needs time to set up protective gear. According to latest recommendations, appropriate personal protective equipment (PPE) should include gowns, surgical gloves, protective eyewear, full face shields, disposable caps, shoe covers, and a N95/99/100 mask [<xref rid="B93-jcm-09-01683" ref-type="bibr">93</xref>,<xref rid="B94-jcm-09-01683" ref-type="bibr">94</xref>,<xref rid="B95-jcm-09-01683" ref-type="bibr">95</xref>]. However, this perspective has mostly formed by the experience with SARS in 2005. Although protection of healthcare workers is essential, especially during this outbreak, which is seeing high rates of infections among healthcare personnel [<xref rid="B96-jcm-09-01683" ref-type="bibr">96</xref>], this setting-up may contribute to introducing another &#x0201c;Covid-19 related delay&#x0201d; in treating STEMI (<xref ref-type="fig" rid="jcm-09-01683-f001">Figure 1</xref>). Tam et al., in a previously mentioned letter, found that device times in catheterization labs were higher during the Covid-19 outbreak when compared to 2018&#x02013;2019 times during office and non-office hours, respectively (catheterization lab: 33 min (IQ: range 21&#x02013;37) vs. 20.5 min (IQ: range 16&#x02013;27.75) vs. 24 min (IQ: range 18&#x02013;30), respectively) [<xref rid="B77-jcm-09-01683" ref-type="bibr">77</xref>]. Importantly, most catheterization labs have either normal or positive ventilation systems and are not designed for infection isolation, meaning that terminals must be cleaned following the procedure is needed, leading to eventual further delays for subsequent procedures [<xref rid="B93-jcm-09-01683" ref-type="bibr">93</xref>]. If possible, in order to avoid SARS-CoV-2 spreading, critical patients should be intubated if needed prior to arrival at the catheterization laboratory.</p></sec><sec id="sec3dot4-jcm-09-01683"><title>3.4. Drug Treatment </title><p>Among drugs commonly used to treat ACS patients, care should be taken when administering antiplatelet therapy. Clopidogrel and ticagrelor have specific interactions with lopinavir&#x02013;ritonavir, a combination of antiviral drugs that have previously been used to treat SARS and MERS, having inhibitory activity against SARS-CoV and MERS-CoV in vitro and in an animal models [<xref rid="B97-jcm-09-01683" ref-type="bibr">97</xref>,<xref rid="B98-jcm-09-01683" ref-type="bibr">98</xref>]. In though in a randomized, controlled, open-label trial conducted by Cao et al., hospitalized adult patients with severe Covid-19 showed no benefit with lopinavir&#x02013;ritonavir treatment beyond standard care, this drug combination is still used worldwide and is awaiting future trials that may help to confirm or exclude the possibility of a treatment benefit [<xref rid="B99-jcm-09-01683" ref-type="bibr">99</xref>]. Lopinavir&#x02013;ritonavir should not be used in combination with clopidogrel or ticagrelor due to their potent CYP3A4 inhibition [<xref rid="B100-jcm-09-01683" ref-type="bibr">100</xref>], which results in a diminished effect of clopidogrel and an increased effect of ticagrelor; prasugrel should be used if no contraindications are present, or a testing-guided approach to evaluate platelet function may be considered [<xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>]. Despite some concerns that were raised at the beginning of the pandemic [<xref rid="B102-jcm-09-01683" ref-type="bibr">102</xref>], no evidence of severe adverse events, long-term survival, acute health care utilization, or quality of life in patients with Covid-19 using aspirin and other non-steroidal anti-inflammatory drugs (NSAIDS) has been provided, as stated by the WHO [<xref rid="B103-jcm-09-01683" ref-type="bibr">103</xref>]. It may be assumed that low-dose aspirin can be safely used as antiplatelet drug in Covid-19 patients.</p><p>Additionally, atorvastatin and rosuvastatin should be started at the lowest possible dose when coadministered with lopinavir&#x02013;ritonavir, since these antiviral drugs inhibit CYP3A4, OATTP1B1, and BCRP, which have roles in the metabolism of statins [<xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>]. Beta-blockers&#x02014;especially metoprolol&#x02014;should be administered cautiously in patients consuming chloroquine or hydroxychloroquine due to CYP2D6 inhibition [<xref rid="B104-jcm-09-01683" ref-type="bibr">104</xref>] and the potential role of hydroxychloroquine in reducing heart rate [<xref rid="B105-jcm-09-01683" ref-type="bibr">105</xref>]. </p><p>Renin&#x02013;angiotensin&#x02013;aldosterone system (RAAS)-related drugs (such as ACE inhibitors and angiotensin II receptor blockers, ARBs) are a cornerstone of therapy after MI, since maintenance of therapy in the days to weeks after the index event has been shown to reduce early mortality [<xref rid="B106-jcm-09-01683" ref-type="bibr">106</xref>]. Despite a lack of evidence of drug consumption or discontinuation in these patients included in the previous mentioned studies, it has been hypothesized that abrupt withdrawal of RAAS inhibitors in high-risk patients, especially those who have heart failure or previous MI, may result in clinical instability and adverse outcomes [<xref rid="B107-jcm-09-01683" ref-type="bibr">107</xref>,<xref rid="B108-jcm-09-01683" ref-type="bibr">108</xref>] and may eventually be related to myocardial injury.</p><p>Antivirals drugs used for SARS-CoV-2 infection treatment may have potential interactions with oral anticoagulants (OACs). Several case reports have highlighted the necessity of augmented doses of warfarin in patients treated with ribavirin; the international normalized ratio (INR) should be monitored carefully in these patients [<xref rid="B109-jcm-09-01683" ref-type="bibr">109</xref>,<xref rid="B110-jcm-09-01683" ref-type="bibr">110</xref>]. Due to the inhibitory effect of lopinavir&#x02013;ritonavir on CYP3A4, which is involved in the hepatic clearance of some novel OACs, rivaroxaban should be avoided and apixaban should be administered at 50% of the standard dose [<xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>]. Given the potential interactions, low molecular weight heparins or unfractionated heparin should be preferred over OACs; moreover, the first evidence showed decreased mortality in most severe Covid-19 patients with coagulopathy [<xref rid="B111-jcm-09-01683" ref-type="bibr">111</xref>]. Drugs that are potentially useful for treatment of acute coronary syndromes and coronary artery disease and their potential interactions are summarized in <xref rid="jcm-09-01683-t004" ref-type="table">Table 4</xref>.</p></sec></sec><sec sec-type="conclusions" id="sec4-jcm-09-01683"><title>4. Conclusions</title><p>Despite being eclipsed by Covid-19 outbreak, acute coronary syndromes are still a major cause of morbidity and mortality worldwide and should not be overshadowed in this era, especially because of the possible physiopathological links (currently unexplored) with SARS-CoV-2 infection.</p><p>Given the limited heterogeneity of data published in recent months, the potential overlapping symptomatology between ACS and SARS-CoV-2 infection, and the underestimation of ACS cases during Covid-19 outbreak, more reliable data are needed to estimate the real prevalence of ACS during this pandemic. Although reports to date suggest that cTn elevation in Covid-19 may be related more to myocardial injury or type 2 MI than to type 1 MI, consistent with our analysis, more data are needed to properly understand all mechanisms that may induce ACS in SARS-CoV-2 infection.</p><p>All efforts made during the last decades to develop strategies to facilitate transfer of ACS patients in whom AMI is suspected directly to the hospital offering 24/7 PCI-mediated reperfusion therapy should not be forgotten. Specific protocols to balance infective risks related to Covid-19 and optimal ACS management should be implemented (especially STEMI), without delays and with preferential PCI treatment whenever possible.</p></sec><sec><title>Authors Contributions</title><p>M.S., C.G., M.M., and G.B.F. conceived of this review. M.S., C.G., and A.G. structured and organized this review. M.S. and C.G. revised the literature and synthesized study data. M.S. and C.G. wrote the original draft of this paper. M.M. and G.B.F. supervised the entire work as senior authors. G.B.-Z., F.D., A.P., M.V., F.F., and M.M. provided expert commentary on how to manage ischemic patients during the Covid-19 pandemic due to their expertise in treating coronary artery disease and myocardial infarction. M.G. provided expert commentary on links between respiratory infections and myocardial involvement, and on infectious risk in ischemic patients during Covid-19 pandemic due to his expertise in infectious disease. G.B.-Z., F.D., A.P., A.G., G.M., M.V., M.G., F.F., M.M., and G.B.F. revised and edited the original draft of this paper. M.S. and C.G. updated this review by analyzing the latest published studies and reports. All authors have read and approved the submitted version. </p></sec></body><back><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest related to this work.</p></notes><ref-list><title>References</title><ref id="B1-jcm-09-01683"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Xiang</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title><source>JAMA J. Am. Med. Assoc.</source><year>2020</year><volume>323</volume><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id><?supplied-pmid 32031570?><pub-id pub-id-type="pmid">32031570</pub-id></element-citation></ref><ref id="B2-jcm-09-01683"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livingston</surname><given-names>E.</given-names></name><name><surname>Bucher</surname><given-names>K.</given-names></name></person-group><article-title>Coronavirus Disease 2019 (COVID-19) in Italy</article-title><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.4344</pub-id></element-citation></ref><ref id="B3-jcm-09-01683"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>M.L.</given-names></name><name><surname>DeBolt</surname><given-names>C.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name><name><surname>Lofy</surname><given-names>K.H.</given-names></name><name><surname>Wiesman</surname><given-names>J.</given-names></name><name><surname>Bruce</surname><given-names>H.</given-names></name><name><surname>Spitters</surname><given-names>C.</given-names></name><name><surname>Ericson</surname><given-names>K.</given-names></name><name><surname>Wilkerson</surname><given-names>S.</given-names></name><name><surname>Tural</surname><given-names>A.</given-names></name><etal/></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2001191</pub-id><?supplied-pmid 32004427?><pub-id pub-id-type="pmid">32004427</pub-id></element-citation></ref><ref id="B4-jcm-09-01683"><label>4.</label><element-citation publication-type="web"><article-title>Coronavirus Disease 2019 (COVID-19) Situation Report&#x02014;105</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-covid-19-sitrep-105.pdf?sfvrsn=4cdda8af_2">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-covid-19-sitrep-105.pdf?sfvrsn=4cdda8af_2</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-05">(accessed on 5 May 2020)</date-in-citation></element-citation></ref><ref id="B5-jcm-09-01683"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="B6-jcm-09-01683"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>S.</given-names></name><name><surname>Qin</surname><given-names>M.</given-names></name><name><surname>Shen</surname><given-names>B.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Gong</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China</article-title><source>JAMA Cardiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.0950</pub-id><?supplied-pmid 32211816?><pub-id pub-id-type="pmid">32211816</pub-id></element-citation></ref><ref id="B7-jcm-09-01683"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>T.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wan</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name></person-group><article-title>Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)</article-title><source>JAMA Cardiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1017</pub-id><?supplied-pmid 32219356?><pub-id pub-id-type="pmid">32219356</pub-id></element-citation></ref><ref id="B8-jcm-09-01683"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remuzzi</surname><given-names>A.</given-names></name><name><surname>Remuzzi</surname><given-names>G.</given-names></name></person-group><article-title>COVID-19 and Italy: What next?</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1225</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30627-9</pub-id><pub-id pub-id-type="pmid">32178769</pub-id></element-citation></ref><ref id="B9-jcm-09-01683"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisen</surname><given-names>A.</given-names></name><name><surname>Giugliano</surname><given-names>R.P.</given-names></name><name><surname>Braunwald</surname><given-names>E.</given-names></name></person-group><article-title>Updates on acute coronary syndrome: A review</article-title><source>JAMA Cardiol.</source><year>2016</year><volume>1</volume><fpage>718</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1001/jamacardio.2016.2049</pub-id><pub-id pub-id-type="pmid">27438381</pub-id></element-citation></ref><ref id="B10-jcm-09-01683"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Townsend</surname><given-names>N.</given-names></name><name><surname>Wilson</surname><given-names>L.</given-names></name><name><surname>Bhatnagar</surname><given-names>P.</given-names></name><name><surname>Wickramasinghe</surname><given-names>K.</given-names></name><name><surname>Rayner</surname><given-names>M.</given-names></name><name><surname>Nichols</surname><given-names>M.</given-names></name></person-group><article-title>Cardiovascular disease in Europe: Epidemiological update 2016</article-title><source>Eur. Heart J.</source><year>2016</year><volume>37</volume><fpage>3232</fpage><lpage>3245</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw334</pub-id><pub-id pub-id-type="pmid">27523477</pub-id></element-citation></ref><ref id="B11-jcm-09-01683"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>E.A.</given-names></name><name><surname>Wenger</surname><given-names>N.K.</given-names></name><name><surname>Brindis</surname><given-names>R.G.</given-names></name><name><surname>Casey</surname><given-names>D.E.</given-names></name><name><surname>Ganiats</surname><given-names>T.G.</given-names></name><name><surname>Holmes</surname><given-names>D.R.</given-names></name><name><surname>Jaffe</surname><given-names>A.S.</given-names></name><name><surname>Jneid</surname><given-names>H.</given-names></name><name><surname>Kelly</surname><given-names>R.F.</given-names></name><name><surname>Kontos</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>2014 AHA/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes: A report of the American college of cardiology/American heart association task force on practice guidelines</article-title><source>Circulation</source><year>2014</year><volume>130</volume><fpage>e344</fpage><lpage>e426</lpage><pub-id pub-id-type="pmid">25249585</pub-id></element-citation></ref><ref id="B12-jcm-09-01683"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roffi</surname><given-names>M.</given-names></name><name><surname>Patrono</surname><given-names>C.</given-names></name><name><surname>Collet</surname><given-names>J.P.</given-names></name><name><surname>Mueller</surname><given-names>C.</given-names></name><name><surname>Valgimigli</surname><given-names>M.</given-names></name><name><surname>Andreotti</surname><given-names>F.</given-names></name><name><surname>Bax</surname><given-names>J.J.</given-names></name><name><surname>Borger</surname><given-names>M.A.</given-names></name><name><surname>Brotons</surname><given-names>C.</given-names></name><name><surname>Chew</surname><given-names>D.P.</given-names></name><etal/></person-group><article-title>2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)</article-title><source>Eur. Heart J.</source><year>2016</year><volume>37</volume><fpage>267</fpage><lpage>315</lpage><?supplied-pmid 26320110?><pub-id pub-id-type="pmid">26320110</pub-id></element-citation></ref><ref id="B13-jcm-09-01683"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K.</given-names></name><name><surname>Alpert</surname><given-names>J.S.</given-names></name><name><surname>Jaffe</surname><given-names>A.S.</given-names></name><name><surname>Chaitman</surname><given-names>B.R.</given-names></name><name><surname>Bax</surname><given-names>J.J.</given-names></name><name><surname>Morrow</surname><given-names>D.A.</given-names></name><name><surname>White</surname><given-names>H.D.</given-names></name><name><surname>Mickley</surname><given-names>H.</given-names></name><name><surname>Crea</surname><given-names>F.</given-names></name><name><surname>Van De Werf</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Fourth universal definition of myocardial infarction (2018)</article-title><source>Eur. Heart J.</source><year>2019</year><volume>40</volume><fpage>237</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehy462</pub-id></element-citation></ref><ref id="B14-jcm-09-01683"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K.</given-names></name><name><surname>Mair</surname><given-names>J.</given-names></name><name><surname>Katus</surname><given-names>H.</given-names></name><name><surname>Plebani</surname><given-names>M.</given-names></name><name><surname>Venge</surname><given-names>P.</given-names></name><name><surname>Collinson</surname><given-names>P.</given-names></name><name><surname>Lindahl</surname><given-names>B.</given-names></name><name><surname>Giannitsis</surname><given-names>E.</given-names></name><name><surname>Hasin</surname><given-names>Y.</given-names></name><name><surname>Galvani</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Recommendations for the use of cardiac troponin measurement in acute cardiac care</article-title><source>Eur. Heart J.</source><year>2010</year><volume>31</volume><fpage>2197</fpage><lpage>2204</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehq251</pub-id><?supplied-pmid 20685679?><pub-id pub-id-type="pmid">20685679</pub-id></element-citation></ref><ref id="B15-jcm-09-01683"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Januzzi</surname><given-names>J.L.</given-names></name><name><surname>Sandoval</surname><given-names>Y.</given-names></name></person-group><article-title>The many faces of type 2 myocardial infarction</article-title><source>J. Am. Coll. Cardiol.</source><year>2017</year><volume>70</volume><fpage>1569</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.07.784</pub-id><pub-id pub-id-type="pmid">28935033</pub-id></element-citation></ref><ref id="B16-jcm-09-01683"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smilowitz</surname><given-names>N.R.</given-names></name><name><surname>Weiss</surname><given-names>M.C.</given-names></name><name><surname>Mauricio</surname><given-names>R.</given-names></name><name><surname>Mahajan</surname><given-names>A.M.</given-names></name><name><surname>Dugan</surname><given-names>K.E.</given-names></name><name><surname>Devanabanda</surname><given-names>A.</given-names></name><name><surname>Pulgarin</surname><given-names>C.</given-names></name><name><surname>Gianos</surname><given-names>E.</given-names></name><name><surname>Shah</surname><given-names>B.</given-names></name><name><surname>Sedlis</surname><given-names>S.P.</given-names></name><etal/></person-group><article-title>Provoking conditions, management and outcomes of type 2 myocardial infarction and myocardial necrosis</article-title><source>Int. J. Cardiol.</source><year>2016</year><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.05.045</pub-id></element-citation></ref><ref id="B17-jcm-09-01683"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>G.Y.</given-names></name><name><surname>Herscovici</surname><given-names>G.</given-names></name><name><surname>Korenfeld</surname><given-names>R.</given-names></name><name><surname>Matetzky</surname><given-names>S.</given-names></name><name><surname>Gottlieb</surname><given-names>S.</given-names></name><name><surname>Alon</surname><given-names>D.</given-names></name><name><surname>Gevrielov-Yusim</surname><given-names>N.</given-names></name><name><surname>Iakobishvili</surname><given-names>Z.</given-names></name><name><surname>Fuchs</surname><given-names>S.</given-names></name></person-group><article-title>Type-II myocardial infarction&#x02014;Patient characteristics, management and outcomes</article-title><source>PLoS ONE</source><year>2014</year><pub-id pub-id-type="doi">10.1371/journal.pone.0084285</pub-id></element-citation></ref><ref id="B18-jcm-09-01683"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G.</given-names></name><name><surname>Sanchis-Gomar</surname><given-names>F.</given-names></name><name><surname>Cervellin</surname><given-names>G.</given-names></name></person-group><article-title>Chest pain, dyspnea and other symptoms in patients with type 1 and 2 myocardial infarction. A literature review</article-title><source>Int. J. Cardiol.</source><year>2016</year><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.04.045</pub-id></element-citation></ref><ref id="B19-jcm-09-01683"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoval</surname><given-names>Y.</given-names></name><name><surname>Smith</surname><given-names>S.W.</given-names></name><name><surname>Sexter</surname><given-names>A.</given-names></name><name><surname>Schulz</surname><given-names>K.</given-names></name><name><surname>Apple</surname><given-names>F.S.</given-names></name></person-group><article-title>Use of objective evidence of myocardial ischemia to facilitate the diagnostic and prognostic distinction between type 2 myocardial infarction and myocardial injury</article-title><source>Eur. Hear. J. Acute Cardiovasc. Care</source><year>2020</year><volume>9</volume><fpage>62</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1177/2048872618787796</pub-id></element-citation></ref><ref id="B20-jcm-09-01683"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoval</surname><given-names>Y.</given-names></name><name><surname>Thygesen</surname><given-names>K.</given-names></name></person-group><article-title>Myocardial infarction type 2 and myocardial injury</article-title><source>Clin. Chem.</source><year>2017</year><volume>63</volume><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2016.255521</pub-id><pub-id pub-id-type="pmid">28062614</pub-id></element-citation></ref><ref id="B21-jcm-09-01683"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arlati</surname><given-names>S.</given-names></name><name><surname>Casella</surname><given-names>G.P.</given-names></name><name><surname>Lanzani</surname><given-names>M.</given-names></name><name><surname>Brenna</surname><given-names>S.</given-names></name><name><surname>Prencipe</surname><given-names>L.</given-names></name><name><surname>Marocchi</surname><given-names>A.</given-names></name><name><surname>Gandini</surname><given-names>C.</given-names></name></person-group><article-title>Myocardial necrosis in ICU patients with acute non-cardiac disease: A prospective study</article-title><source>Intensive Care Med.</source><year>2000</year><volume>26</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1007/s001340050008</pub-id><pub-id pub-id-type="pmid">10663277</pub-id></element-citation></ref><ref id="B22-jcm-09-01683"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musher</surname><given-names>D.M.</given-names></name><name><surname>Abers</surname><given-names>M.S.</given-names></name><name><surname>Corrales-Medina</surname><given-names>V.F.</given-names></name></person-group><article-title>Acute infection and myocardial infarction</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1808137</pub-id><?supplied-pmid 30625066?><pub-id pub-id-type="pmid">30625066</pub-id></element-citation></ref><ref id="B23-jcm-09-01683"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochi</surname><given-names>A.N.</given-names></name><name><surname>Tagliari</surname><given-names>A.P.</given-names></name><name><surname>Forleo</surname><given-names>G.B.</given-names></name><name><surname>Fassini</surname><given-names>G.M.</given-names></name><name><surname>Tondo</surname><given-names>C.</given-names></name></person-group><article-title>Cardiac and arrhythmic complications in patients with COVID-19</article-title><source>J. Cardiovasc. Electrophysiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/jce.14479</pub-id><?supplied-pmid 32270559?><pub-id pub-id-type="pmid">32270559</pub-id></element-citation></ref><ref id="B24-jcm-09-01683"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandoval</surname><given-names>Y.</given-names></name><name><surname>Jaffe</surname><given-names>A.S.</given-names></name></person-group><article-title>Type 2 Myocardial Infarction: JACC Review Topic of the Week</article-title><source>J. Am. Coll. Cardiol.</source><year>2019</year><volume>73</volume><fpage>1846</fpage><lpage>1860</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.02.018</pub-id><?supplied-pmid 30975302?><pub-id pub-id-type="pmid">30975302</pub-id></element-citation></ref><ref id="B25-jcm-09-01683"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>J.A.</given-names></name><name><surname>Warren-Gash</surname><given-names>C.</given-names></name></person-group><article-title>Cardiovascular complications of acute respiratory infections: Current research and future directions</article-title><source>Expert Rev. Anti. Infect.</source><year>2019</year><volume>17</volume><fpage>939</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1080/14787210.2019.1689817</pub-id><?supplied-pmid 31684779?><pub-id pub-id-type="pmid">31684779</pub-id></element-citation></ref><ref id="B26-jcm-09-01683"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guest</surname><given-names>T.M.</given-names></name><name><surname>Ramanathan</surname><given-names>A.V.</given-names></name><name><surname>Tuteur</surname><given-names>P.G.</given-names></name><name><surname>Schechtman</surname><given-names>K.B.</given-names></name><name><surname>Ladenson</surname><given-names>J.H.</given-names></name><name><surname>Jaffe</surname><given-names>A.S.</given-names></name></person-group><article-title>Myocardial Injury in Critically Ill Patients: A Frequently Unrecognized Complication</article-title><source>JAMA J. Am. Med. Assoc.</source><year>1995</year><volume>273</volume><fpage>1945</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1001/jama.1995.03520480065042</pub-id></element-citation></ref><ref id="B27-jcm-09-01683"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpick</surname><given-names>R.J.</given-names></name><name><surname>Pratt</surname><given-names>P.C.</given-names></name><name><surname>Asmundsson</surname><given-names>T.</given-names></name><name><surname>Kilburn</surname><given-names>K.H.</given-names></name></person-group><article-title>Pathological findings in respiratory failure. Goblet cell metaplasia, alveolar damage, and myocardial infarction</article-title><source>Ann. Intern. Med.</source><year>1970</year><volume>72</volume><fpage>189</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-72-2-189</pub-id><pub-id pub-id-type="pmid">5412486</pub-id></element-citation></ref><ref id="B28-jcm-09-01683"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soeiro</surname><given-names>A.d.M.</given-names></name><name><surname>Ruppert</surname><given-names>A.D.</given-names></name><name><surname>Canzian</surname><given-names>M.</given-names></name><name><surname>Capelozzi</surname><given-names>V.L.</given-names></name><name><surname>Serrano</surname><given-names>C.V.</given-names></name></person-group><article-title>Postmortem diagnosis of Acutemyocardial infarction in patients with acute respiratory failure - Demographics, etiologic and pulmonary Histologic analysis</article-title><source>Clinics</source><year>2012</year><pub-id pub-id-type="doi">10.6061/clinics/2012(03)02</pub-id></element-citation></ref><ref id="B29-jcm-09-01683"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stary</surname><given-names>H.C.</given-names></name><name><surname>Chandler</surname><given-names>A.B.</given-names></name><name><surname>Dinsmore</surname><given-names>R.E.</given-names></name><name><surname>Fuster</surname><given-names>V.</given-names></name><name><surname>Glagov</surname><given-names>S.</given-names></name><name><surname>Insull</surname><given-names>W.</given-names></name><name><surname>Rosenfeld</surname><given-names>M.E.</given-names></name><name><surname>Schwartz</surname><given-names>C.J.</given-names></name><name><surname>Wagner</surname><given-names>W.D.</given-names></name><name><surname>Wissler</surname><given-names>R.W.</given-names></name></person-group><article-title>A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the council on arteriosclerosis, American heart association</article-title><source>Circulation</source><year>1995</year><volume>92</volume><fpage>1355</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.92.5.1355</pub-id><pub-id pub-id-type="pmid">7648691</pub-id></element-citation></ref><ref id="B30-jcm-09-01683"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauriello</surname><given-names>A.</given-names></name><name><surname>Sangiorgi</surname><given-names>G.</given-names></name><name><surname>Fratoni</surname><given-names>S.</given-names></name><name><surname>Palmieri</surname><given-names>G.</given-names></name><name><surname>Bonanno</surname><given-names>E.</given-names></name><name><surname>Anemona</surname><given-names>L.</given-names></name><name><surname>Schwartz</surname><given-names>R.S.</given-names></name><name><surname>Spagnoli</surname><given-names>L.G.</given-names></name></person-group><article-title>Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: A histopathologic study of patients dying of acute myocardial infarction</article-title><source>J. Am. Coll. Cardiol.</source><year>2005</year><volume>45</volume><fpage>1585</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2005.01.054</pub-id><pub-id pub-id-type="pmid">15893171</pub-id></element-citation></ref><ref id="B31-jcm-09-01683"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaynar</surname><given-names>A.M.</given-names></name><name><surname>Yende</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Frederick</surname><given-names>D.R.</given-names></name><name><surname>Chambers</surname><given-names>R.</given-names></name><name><surname>Burton</surname><given-names>C.L.</given-names></name><name><surname>Carter</surname><given-names>M.</given-names></name><name><surname>Stolz</surname><given-names>D.B.</given-names></name><name><surname>Agostini</surname><given-names>B.</given-names></name><name><surname>Gregory</surname><given-names>A.D.</given-names></name><etal/></person-group><article-title>Effects of intra-abdominal sepsis on atherosclerosis in mice</article-title><source>Crit. Care</source><year>2014</year><volume>18</volume><pub-id pub-id-type="doi">10.1186/s13054-014-0469-1</pub-id></element-citation></ref><ref id="B32-jcm-09-01683"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madjid</surname><given-names>M.</given-names></name><name><surname>Vela</surname><given-names>D.</given-names></name><name><surname>Khalili-Tabrizi</surname><given-names>H.</given-names></name><name><surname>Casscells</surname><given-names>S.W.</given-names></name><name><surname>Litovsky</surname><given-names>S.</given-names></name></person-group><article-title>Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: Clues to the triggering effect of acute infections on acute coronary syndromes</article-title><source>Tex. Heart Inst. J.</source><year>2007</year><volume>34</volume><fpage>11</fpage><lpage>18</lpage><?supplied-pmid 17420787?><pub-id pub-id-type="pmid">17420787</pub-id></element-citation></ref><ref id="B33-jcm-09-01683"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crea</surname><given-names>F.</given-names></name><name><surname>Liuzzo</surname><given-names>G.</given-names></name></person-group><article-title>Pathogenesis of acute coronary syndromes</article-title><source>J. Am. Coll. Cardiol.</source><year>2013</year><volume>61</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2012.07.064</pub-id><?supplied-pmid 23158526?><pub-id pub-id-type="pmid">23158526</pub-id></element-citation></ref><ref id="B34-jcm-09-01683"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P.</given-names></name></person-group><article-title>Mechanisms of acute coronary syndromes and their implications for therapy</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>2004</fpage><lpage>2013</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1216063</pub-id><?supplied-pmid 23697515?><pub-id pub-id-type="pmid">23697515</pub-id></element-citation></ref><ref id="B35-jcm-09-01683"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuster</surname><given-names>V.</given-names></name><name><surname>Badimon</surname><given-names>L.</given-names></name><name><surname>Badimon</surname><given-names>J.J.</given-names></name><name><surname>Chesebro</surname><given-names>J.H.</given-names></name><name><surname>Epstein</surname><given-names>F.H.</given-names></name></person-group><article-title>The pathogenesis of coronary artery disease and the acute coronary syndromes</article-title><source>N. Engl. J. Med.</source><year>1992</year><volume>326</volume><fpage>242</fpage><lpage>250</lpage><?supplied-pmid 1727977?><pub-id pub-id-type="pmid">1727977</pub-id></element-citation></ref><ref id="B36-jcm-09-01683"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>P.P.</given-names></name><name><surname>Blet</surname><given-names>A.</given-names></name><name><surname>Smyth</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name></person-group><article-title>The Science Underlying COVID-19: Implications for the cardiovascular system</article-title><source>Circulation</source><year>2020</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047549</pub-id></element-citation></ref><ref id="B37-jcm-09-01683"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harskamp</surname><given-names>R.E.</given-names></name><name><surname>Van Ginkel</surname><given-names>M.W.</given-names></name></person-group><article-title>Acute respiratory tract infections: A potential trigger for the acute coronary syndrome</article-title><source>Ann. Med.</source><year>2008</year><volume>40</volume><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1080/07853890701753672</pub-id><pub-id pub-id-type="pmid">18293142</pub-id></element-citation></ref><ref id="B38-jcm-09-01683"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>T.T.</given-names></name><name><surname>Mairuhu</surname><given-names>A.T.A.</given-names></name><name><surname>De Kruif</surname><given-names>M.D.</given-names></name><name><surname>Klein</surname><given-names>S.K.</given-names></name><name><surname>Gerdes</surname><given-names>V.E.A.</given-names></name><name><surname>Ten Cate</surname><given-names>H.</given-names></name><name><surname>Brandjes</surname><given-names>D.P.M.</given-names></name><name><surname>Levi</surname><given-names>M.</given-names></name><name><surname>Van Gorp</surname><given-names>E.C.M.</given-names></name></person-group><article-title>Infections and endothelial cells</article-title><source>Cardiovasc. Res.</source><year>2003</year><volume>60</volume><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(03)00354-7</pub-id><pub-id pub-id-type="pmid">14522405</pub-id></element-citation></ref><ref id="B39-jcm-09-01683"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>M.</given-names></name><name><surname>Van Der Poll</surname><given-names>T.</given-names></name><name><surname>B&#x000fc;ller</surname><given-names>H.R.</given-names></name></person-group><article-title>Bidirectional relation between inflammation and coagulation</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>2698</fpage><lpage>2704</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000131660.51520.9A</pub-id><pub-id pub-id-type="pmid">15184294</pub-id></element-citation></ref><ref id="B40-jcm-09-01683"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>J.J.</given-names></name><name><surname>Voora</surname><given-names>D.</given-names></name><name><surname>Cyr</surname><given-names>D.D.</given-names></name><name><surname>Lucas</surname><given-names>J.E.</given-names></name><name><surname>Zaas</surname><given-names>A.K.</given-names></name><name><surname>Woods</surname><given-names>C.W.</given-names></name><name><surname>Newby</surname><given-names>L.K.</given-names></name><name><surname>Kraus</surname><given-names>W.E.</given-names></name><name><surname>Ginsburg</surname><given-names>G.S.</given-names></name></person-group><article-title>Gene expression profiles link respiratory viral infection, platelet response to aspirin, and acute myocardial infarction</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0132259</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0132259</pub-id><pub-id pub-id-type="pmid">26193668</pub-id></element-citation></ref><ref id="B41-jcm-09-01683"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>S.D.</given-names></name></person-group><article-title>Excess mortality from causes other than influenza and pneumonia during influenza epidemics</article-title><source>Public Health Rep.</source><year>1932</year><pub-id pub-id-type="doi">10.2307/4580606</pub-id></element-citation></ref><ref id="B42-jcm-09-01683"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smeeth</surname><given-names>L.</given-names></name><name><surname>Thomas</surname><given-names>S.L.</given-names></name><name><surname>Hall</surname><given-names>A.J.</given-names></name><name><surname>Hubbard</surname><given-names>R.</given-names></name><name><surname>Farrington</surname><given-names>P.</given-names></name><name><surname>Vallance</surname><given-names>P.</given-names></name></person-group><article-title>Risk of myocardial infarction and stroke after acute infection or vaccination</article-title><source>N. Engl. J. Med.</source><year>2004</year><pub-id pub-id-type="doi">10.1056/NEJMoa041747</pub-id><?supplied-pmid 15602021?><pub-id pub-id-type="pmid">15602021</pub-id></element-citation></ref><ref id="B43-jcm-09-01683"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>J.C.</given-names></name><name><surname>Schwartz</surname><given-names>K.L.</given-names></name><name><surname>Campitelli</surname><given-names>M.A.</given-names></name><name><surname>Chung</surname><given-names>H.</given-names></name><name><surname>Crowcroft</surname><given-names>N.S.</given-names></name><name><surname>Karnauchow</surname><given-names>T.</given-names></name><name><surname>Katz</surname><given-names>K.</given-names></name><name><surname>Ko</surname><given-names>D.T.</given-names></name><name><surname>McGeer</surname><given-names>A.J.</given-names></name><name><surname>McNally</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Acute myocardial infarction after laboratory-confirmed influenza infection</article-title><source>N. Engl. J. Med.</source><year>2018</year><pub-id pub-id-type="doi">10.1056/NEJMoa1702090</pub-id><?supplied-pmid 29365305?><pub-id pub-id-type="pmid">29365305</pub-id></element-citation></ref><ref id="B44-jcm-09-01683"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren-Gash</surname><given-names>C.</given-names></name><name><surname>Geretti</surname><given-names>A.M.</given-names></name><name><surname>Hamilton</surname><given-names>G.</given-names></name><name><surname>Rakhit</surname><given-names>R.D.</given-names></name><name><surname>Smeeth</surname><given-names>L.</given-names></name><name><surname>Hayward</surname><given-names>A.C.</given-names></name></person-group><article-title>Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza A H1N1 pandemic in London: A case-control study</article-title><source>BMJ Open</source><year>2013</year><volume>3</volume><fpage>e002604</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2013-002604</pub-id><?supplied-pmid 23645915?><pub-id pub-id-type="pmid">23645915</pub-id></element-citation></ref><ref id="B45-jcm-09-01683"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Violi</surname><given-names>F.</given-names></name><name><surname>Cangemi</surname><given-names>R.</given-names></name><name><surname>Falcone</surname><given-names>M.</given-names></name><name><surname>Taliani</surname><given-names>G.</given-names></name><name><surname>Pieralli</surname><given-names>F.</given-names></name><name><surname>Vannucchi</surname><given-names>V.</given-names></name><name><surname>Nozzoli</surname><given-names>C.</given-names></name><name><surname>Venditti</surname><given-names>M.</given-names></name><name><surname>Chirinos</surname><given-names>J.A.</given-names></name><name><surname>Corrales-Medina</surname><given-names>V.F.</given-names></name></person-group><article-title>Cardiovascular complications and short-term mortality risk in community-acquired pneumonia</article-title><source>Clin. Infect. Dis.</source><year>2017</year><volume>64</volume><fpage>1486</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1093/cid/cix164</pub-id><pub-id pub-id-type="pmid">28205683</pub-id></element-citation></ref><ref id="B46-jcm-09-01683"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musher</surname><given-names>D.M.</given-names></name><name><surname>Rueda</surname><given-names>A.M.</given-names></name><name><surname>Kaka</surname><given-names>A.S.</given-names></name><name><surname>Mapara</surname><given-names>S.M.</given-names></name></person-group><article-title>The Association between Pneumococcal Pneumonia and Acute Cardiac Events</article-title><source>Clin. Infect. Dis.</source><year>2007</year><pub-id pub-id-type="doi">10.1086/518849</pub-id></element-citation></ref><ref id="B47-jcm-09-01683"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrales-Medina</surname><given-names>V.F.</given-names></name><name><surname>Alvarez</surname><given-names>K.N.</given-names></name><name><surname>Weissfeld</surname><given-names>L.A.</given-names></name><name><surname>Angus</surname><given-names>D.C.</given-names></name><name><surname>Chirinos</surname><given-names>J.A.</given-names></name><name><surname>Chang</surname><given-names>C.C.H.</given-names></name><name><surname>Newman</surname><given-names>A.</given-names></name><name><surname>Loehr</surname><given-names>L.</given-names></name><name><surname>Folsom</surname><given-names>A.R.</given-names></name><name><surname>Elkind</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease</article-title><source>JAMA J. Am. Med. Assoc.</source><year>2015</year><pub-id pub-id-type="doi">10.1001/jama.2014.18229</pub-id></element-citation></ref><ref id="B48-jcm-09-01683"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vejpongsa</surname><given-names>P.</given-names></name><name><surname>Kitkungvan</surname><given-names>D.</given-names></name><name><surname>Madjid</surname><given-names>M.</given-names></name><name><surname>Charitakis</surname><given-names>K.</given-names></name><name><surname>Anderson</surname><given-names>H.V.</given-names></name><name><surname>Arain</surname><given-names>S.</given-names></name><name><surname>Balan</surname><given-names>P.</given-names></name><name><surname>Smalling</surname><given-names>R.W.</given-names></name><name><surname>Dhoble</surname><given-names>A.</given-names></name></person-group><article-title>Outcomes of acute myocardial infarction in patients with influenza and other viral respiratory infections</article-title><source>Am. J. Med.</source><year>2019</year><volume>132</volume><fpage>1173</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2019.05.002</pub-id><pub-id pub-id-type="pmid">31145880</pub-id></element-citation></ref><ref id="B49-jcm-09-01683"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caussin</surname><given-names>C.</given-names></name><name><surname>Escolano</surname><given-names>S.</given-names></name><name><surname>Mustafic</surname><given-names>H.</given-names></name><name><surname>Bataille</surname><given-names>S.</given-names></name><name><surname>Tafflet</surname><given-names>M.</given-names></name><name><surname>Chatignoux</surname><given-names>E.</given-names></name><name><surname>Lambert</surname><given-names>Y.</given-names></name><name><surname>Benamer</surname><given-names>H.</given-names></name><name><surname>Garot</surname><given-names>P.</given-names></name><name><surname>Jabre</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Short-term exposure to environmental parameters and onset of ST elevation myocardial infarction. The CARDIO-ARSIF registry</article-title><source>Int. J. Cardiol.</source><year>2015</year><volume>183</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2015.01.078</pub-id><pub-id pub-id-type="pmid">25662048</pub-id></element-citation></ref><ref id="B50-jcm-09-01683"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruane</surname><given-names>L.</given-names></name><name><surname>Buckley</surname><given-names>T.</given-names></name><name><surname>Hoo</surname><given-names>S.Y.S.</given-names></name><name><surname>Hansen</surname><given-names>P.S.</given-names></name><name><surname>McCormack</surname><given-names>C.</given-names></name><name><surname>Shaw</surname><given-names>E.</given-names></name><name><surname>Fethney</surname><given-names>J.</given-names></name><name><surname>Tofler</surname><given-names>G.H.</given-names></name></person-group><article-title>Triggering of acute myocardial infarction by respiratory infection</article-title><source>Intern. Med. J.</source><year>2017</year><volume>47</volume><fpage>522</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1111/imj.13377</pub-id><pub-id pub-id-type="pmid">28105763</pub-id></element-citation></ref><ref id="B51-jcm-09-01683"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.M.</given-names></name><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Cheng</surname><given-names>V.C.C.</given-names></name><name><surname>Chan</surname><given-names>K.S.</given-names></name><name><surname>Hung</surname><given-names>I.F.N.</given-names></name><name><surname>Poon</surname><given-names>L.L.M.</given-names></name><name><surname>Law</surname><given-names>K.I.</given-names></name><name><surname>Tang</surname><given-names>B.S.F.</given-names></name><name><surname>Hon</surname><given-names>T.Y.W.</given-names></name><name><surname>Chan</surname><given-names>C.S.</given-names></name><etal/></person-group><article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study</article-title><source>Lancet</source><year>2003</year><pub-id pub-id-type="doi">10.1016/S0140-6736(03)13412-5</pub-id></element-citation></ref><ref id="B52-jcm-09-01683"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>P.Y.</given-names></name><name><surname>Chui</surname><given-names>P.</given-names></name><name><surname>Ling</surname><given-names>A.E.</given-names></name><name><surname>Franks</surname><given-names>T.J.</given-names></name><name><surname>Tai</surname><given-names>D.Y.H.</given-names></name><name><surname>Leo</surname><given-names>Y.S.</given-names></name><name><surname>Kaw</surname><given-names>G.J.L.</given-names></name><name><surname>Wansaicheong</surname><given-names>G.</given-names></name><name><surname>Chan</surname><given-names>K.P.</given-names></name><name><surname>Oon</surname><given-names>L.L.E.</given-names></name><etal/></person-group><article-title>Analysis of deaths during the Severe Acute Respiratory Syndrome (SARS) epidemic in Singapore: Challenges in determining a SARS diagnosis</article-title><source>Arch. Pathol. Lab. Med.</source><year>2004</year><volume>128</volume><fpage>195</fpage><lpage>204</lpage><?supplied-pmid 14736283?><pub-id pub-id-type="pmid">14736283</pub-id></element-citation></ref><ref id="B53-jcm-09-01683"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>M.</given-names></name><name><surname>Heywood</surname><given-names>A.E.</given-names></name><name><surname>Mahimbo</surname><given-names>A.</given-names></name><name><surname>Rahman</surname><given-names>B.</given-names></name><name><surname>Newall</surname><given-names>A.T.</given-names></name><name><surname>MaCintyre</surname><given-names>C.R.</given-names></name></person-group><article-title>Acute myocardial infarction and influenza: A meta-analysis of case-control studies</article-title><source>Heart</source><year>2015</year><pub-id pub-id-type="doi">10.1136/heartjnl-2015-307691</pub-id><?supplied-pmid 26310262?><pub-id pub-id-type="pmid">26310262</pub-id></element-citation></ref><ref id="B54-jcm-09-01683"><label>54.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Summary of Probable SARS Cases with Onset of Illness from 1 November 2002 to 31 July 2003</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/country/table2004_04_21/en/">https://www.who.int/csr/sars/country/table2004_04_21/en/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-04-16">(accessed on 16 April 2020)</date-in-citation></element-citation></ref><ref id="B55-jcm-09-01683"><label>55.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab><collab>EMRO</collab><collab>MERS Outbreaks</collab><collab>MERS-CoV</collab></person-group><article-title>Health Topics</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html">http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-04-16">(accessed on 16 April 2020)</date-in-citation></element-citation></ref><ref id="B56-jcm-09-01683"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badawi</surname><given-names>A.</given-names></name><name><surname>Ryoo</surname><given-names>S.G.</given-names></name></person-group><article-title>Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis</article-title><source>Int. J. Infect. Dis.</source><year>2016</year><volume>49</volume><fpage>129</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2016.06.015</pub-id><?supplied-pmid 27352628?><pub-id pub-id-type="pmid">27352628</pub-id></element-citation></ref><ref id="B57-jcm-09-01683"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>R.</given-names></name><name><surname>Nishiura</surname><given-names>H.</given-names></name><name><surname>Kutsuna</surname><given-names>S.</given-names></name><name><surname>Hayakawa</surname><given-names>K.</given-names></name><name><surname>Ohmagari</surname><given-names>N.</given-names></name></person-group><article-title>Clinical determinants of the severity of Middle East respiratory syndrome (MERS): A systematic review and meta-analysis</article-title><source>BMC Public Health</source><year>2016</year><volume>16</volume><pub-id pub-id-type="doi">10.1186/s12889-016-3881-4</pub-id></element-citation></ref><ref id="B58-jcm-09-01683"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.E.</given-names></name><name><surname>Jung</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>A.</given-names></name></person-group><article-title>MERS transmission and risk factors: A systematic review</article-title><source>BMC Public Health</source><year>2018</year><pub-id pub-id-type="doi">10.1186/s12889-018-5484-8</pub-id></element-citation></ref><ref id="B59-jcm-09-01683"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madjid</surname><given-names>M.</given-names></name><name><surname>Safavi-Naeini</surname><given-names>P.</given-names></name><name><surname>Solomon</surname><given-names>S.D.</given-names></name><name><surname>Vardeny</surname><given-names>O.</given-names></name></person-group><article-title>Potential effects of coronaviruses on the cardiovascular system: A review</article-title><source>JAMA Cardiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1286</pub-id></element-citation></ref><ref id="B60-jcm-09-01683"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhogbani</surname><given-names>T.</given-names></name></person-group><article-title>Acute myocarditis associated with novel middle east respiratory syndrome coronavirus</article-title><source>Ann. Saudi Med.</source><year>2016</year><pub-id pub-id-type="doi">10.5144/0256-4947.2016.78</pub-id></element-citation></ref><ref id="B61-jcm-09-01683"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name></person-group><article-title>Association of influenza virus infection and inflammatory cytokines with acute myocardial infarction</article-title><source>Inflamm. Res.</source><year>2012</year><volume>61</volume><fpage>591</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1007/s00011-012-0449-3</pub-id><pub-id pub-id-type="pmid">22373653</pub-id></element-citation></ref><ref id="B62-jcm-09-01683"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udell</surname><given-names>J.A.</given-names></name><name><surname>Zawi</surname><given-names>R.</given-names></name><name><surname>Bhatt</surname><given-names>D.L.</given-names></name><name><surname>Keshtkar-Jahromi</surname><given-names>M.</given-names></name><name><surname>Gaughran</surname><given-names>F.</given-names></name><name><surname>Phrommintikul</surname><given-names>A.</given-names></name><name><surname>Ciszewski</surname><given-names>A.</given-names></name><name><surname>Vakili</surname><given-names>H.</given-names></name><name><surname>Hoffman</surname><given-names>E.B.</given-names></name><name><surname>Farkouh</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Association between influenza vaccination and cardiovascular outcomes in high-risk patients: A meta-analysis</article-title><source>JAMA J. Am. Med. Assoc.</source><year>2013</year><pub-id pub-id-type="doi">10.1001/jama.2013.279206</pub-id></element-citation></ref><ref id="B63-jcm-09-01683"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacIntyre</surname><given-names>C.R.</given-names></name><name><surname>Mahimbo</surname><given-names>A.</given-names></name><name><surname>Moa</surname><given-names>A.M.</given-names></name><name><surname>Barnes</surname><given-names>M.</given-names></name></person-group><article-title>Influenza vaccine as a coronary intervention for prevention of myocardial infarction</article-title><source>Heart</source><year>2016</year><volume>102</volume><fpage>1953</fpage><lpage>1956</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2016-309983</pub-id><pub-id pub-id-type="pmid">27686519</pub-id></element-citation></ref><ref id="B64-jcm-09-01683"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebsur</surname><given-names>S.</given-names></name><name><surname>Vakil</surname><given-names>E.</given-names></name><name><surname>Oetgen</surname><given-names>W.J.</given-names></name><name><surname>Kumar</surname><given-names>P.N.</given-names></name><name><surname>Lazarous</surname><given-names>D.F.</given-names></name></person-group><article-title>Influenza and coronary artery disease: Exploring a clinical association with myocardial infarction and analyzing the utility of vaccination in prevention of myocardial infarction</article-title><source>Rev. Cardiovasc. Med.</source><year>2014</year><volume>15</volume><fpage>168</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.3909/ricm0692</pub-id><?supplied-pmid 25051134?><pub-id pub-id-type="pmid">25051134</pub-id></element-citation></ref><ref id="B65-jcm-09-01683"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knuuti</surname><given-names>J.</given-names></name><name><surname>Wijns</surname><given-names>W.</given-names></name><name><surname>Achenbach</surname><given-names>S.</given-names></name><name><surname>Agewall</surname><given-names>S.</given-names></name><name><surname>Barbato</surname><given-names>E.</given-names></name><name><surname>Bax</surname><given-names>J.J.</given-names></name><name><surname>Capodanno</surname><given-names>D.</given-names></name><name><surname>Cuisset</surname><given-names>T.</given-names></name><name><surname>Deaton</surname><given-names>C.</given-names></name><name><surname>Dickstein</surname><given-names>K.</given-names></name><etal/></person-group><article-title>2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes</article-title><source>Eur. Heart J.</source><year>2020</year><volume>41</volume><fpage>407</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehz425</pub-id><?supplied-pmid 31504439?><pub-id pub-id-type="pmid">31504439</pub-id></element-citation></ref><ref id="B66-jcm-09-01683"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Xiang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Song</surname><given-names>B.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="B67-jcm-09-01683"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y.Y.</given-names></name><name><surname>Ma</surname><given-names>Y.T.</given-names></name><name><surname>Zhang</surname><given-names>J.Y.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name></person-group><article-title>COVID-19 and the cardiovascular system</article-title><source>Nat. Rev. Cardiol.</source><year>2020</year><volume>17</volume><fpage>259</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/s41569-020-0360-5</pub-id><?supplied-pmid 32139904?><pub-id pub-id-type="pmid">32139904</pub-id></element-citation></ref><ref id="B68-jcm-09-01683"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G.</given-names></name><name><surname>Lavie</surname><given-names>C.J.</given-names></name><name><surname>Sanchis-Gomar</surname><given-names>F.</given-names></name></person-group><article-title>Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis</article-title><source>Prog. Cardiovasc. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.pcad.2020.03.001</pub-id><?supplied-pmid 32169400?><pub-id pub-id-type="pmid">32169400</pub-id></element-citation></ref><ref id="B69-jcm-09-01683"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clerkin</surname><given-names>K.J.</given-names></name><name><surname>Fried</surname><given-names>J.A.</given-names></name><name><surname>Raikhelkar</surname><given-names>J.</given-names></name><name><surname>Sayer</surname><given-names>G.</given-names></name><name><surname>Griffin</surname><given-names>J.M.</given-names></name><name><surname>Masoumi</surname><given-names>A.</given-names></name><name><surname>Jain</surname><given-names>S.S.</given-names></name><name><surname>Burkhoff</surname><given-names>D.</given-names></name><name><surname>Kumaraiah</surname><given-names>D.</given-names></name><name><surname>Rabbani</surname><given-names>L.R.</given-names></name><etal/></person-group><article-title>Coronavirus disease 2019 (COVID-19) and cardiovascular disease</article-title><source>Circulation</source><year>2020</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.046941</pub-id></element-citation></ref><ref id="B70-jcm-09-01683"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibanez</surname><given-names>B.</given-names></name><name><surname>James</surname><given-names>S.</given-names></name><name><surname>Agewall</surname><given-names>S.</given-names></name><name><surname>Antunes</surname><given-names>M.J.</given-names></name><name><surname>Bucciarelli-Ducci</surname><given-names>C.</given-names></name><name><surname>Bueno</surname><given-names>H.</given-names></name><name><surname>Caforio</surname><given-names>A.L.P.</given-names></name><name><surname>Crea</surname><given-names>F.</given-names></name><name><surname>Goudevenos</surname><given-names>J.A.</given-names></name><name><surname>Halvorsen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation</article-title><source>Eur. Heart J.</source><year>2018</year><volume>39</volume><fpage>119</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx393</pub-id><pub-id pub-id-type="pmid">28886621</pub-id></element-citation></ref><ref id="B71-jcm-09-01683"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholz</surname><given-names>K.H.</given-names></name><name><surname>Maier</surname><given-names>S.K.G.</given-names></name><name><surname>Maier</surname><given-names>L.S.</given-names></name><name><surname>Lengenfelder</surname><given-names>B.</given-names></name><name><surname>Jacobshagen</surname><given-names>C.</given-names></name><name><surname>Jung</surname><given-names>J.</given-names></name><name><surname>Fleischmann</surname><given-names>C.</given-names></name><name><surname>Werner</surname><given-names>G.S.</given-names></name><name><surname>Olbrich</surname><given-names>H.G.</given-names></name><name><surname>Ott</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: Results from the German prospective, multicentre FITT-STEMI trial</article-title><source>Eur. Heart J.</source><year>2018</year><pub-id pub-id-type="doi">10.1093/eurheartj/ehy004</pub-id><?supplied-pmid 29452351?><pub-id pub-id-type="pmid">29452351</pub-id></element-citation></ref><ref id="B72-jcm-09-01683"><label>72.</label><element-citation publication-type="web"><article-title>Two Important Messages on COVID-19 and CVD&#x02014;YouTube</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.youtube.com/watch?v=ctNq26xAEx4&#x00026;feature=emb_title">https://www.youtube.com/watch?v=ctNq26xAEx4&#x00026;feature=emb_title</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-04-16">(accessed on 16 April 2020)</date-in-citation></element-citation></ref><ref id="B73-jcm-09-01683"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>S.</given-names></name><name><surname>Albaghdadi</surname><given-names>M.S.</given-names></name><name><surname>Meraj</surname><given-names>P.M.</given-names></name><name><surname>Schmidt</surname><given-names>C.</given-names></name><name><surname>Garberich</surname><given-names>R.</given-names></name><name><surname>Jaffer</surname><given-names>F.A.</given-names></name><name><surname>Dixon</surname><given-names>S.</given-names></name><name><surname>Rade</surname><given-names>J.J.</given-names></name><name><surname>Tannenbaum</surname><given-names>M.</given-names></name><name><surname>Chambers</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic</article-title><source>J. Am. Coll. Cardiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jacc.2020.04.011</pub-id><?supplied-pmid 32283124?><pub-id pub-id-type="pmid">32283124</pub-id></element-citation></ref><ref id="B74-jcm-09-01683"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Leor</surname><given-names>O.</given-names></name><name><surname>Cid-&#x000c1;lvarez</surname><given-names>B.</given-names></name><name><surname>Ojeda</surname><given-names>S.</given-names></name><name><surname>Mart&#x000ed;n-Moreiras</surname><given-names>J.</given-names></name><name><surname>Ram&#x000f3;n Rumoroso</surname><given-names>J.</given-names></name><name><surname>L&#x000f3;pez-Palop</surname><given-names>R.</given-names></name><name><surname>Serrador</surname><given-names>A.</given-names></name><name><surname>Cequier</surname><given-names>&#x000c1;.</given-names></name><name><surname>Romaguera</surname><given-names>R.</given-names></name><name><surname>Cruz</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Impacto de la pandemia de COVID-19 sobre la actividad asistencial en cardiolog&#x000ed;a intervencionista en Espa&#x000f1;a</article-title><source>REC Interv. Cardiol.</source><year>2020</year><pub-id pub-id-type="doi">10.24875/RECIC.M20000120</pub-id></element-citation></ref><ref id="B75-jcm-09-01683"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rosa</surname><given-names>S.</given-names></name><name><surname>Spaccarotella</surname><given-names>C.</given-names></name><name><surname>Basso</surname><given-names>C.</given-names></name><name><surname>Calabr&#x000f2;</surname><given-names>M.P.</given-names></name><name><surname>Curcio</surname><given-names>A.</given-names></name><name><surname>Filardi</surname><given-names>P.P.</given-names></name><name><surname>Mancone</surname><given-names>M.</given-names></name><name><surname>Mercuro</surname><given-names>G.</given-names></name><name><surname>Muscoli</surname><given-names>S.</given-names></name><name><surname>Nodari</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era</article-title><source>Eur. Heart J.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa409</pub-id></element-citation></ref><ref id="B76-jcm-09-01683"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Filippo</surname><given-names>O.</given-names></name><name><surname>D&#x02019;Ascenzo</surname><given-names>F.</given-names></name><name><surname>Angelini</surname><given-names>F.</given-names></name><name><surname>Bocchino</surname><given-names>P.P.</given-names></name><name><surname>Conrotto</surname><given-names>F.</given-names></name><name><surname>Saglietto</surname><given-names>A.</given-names></name><name><surname>Secco</surname><given-names>G.G.</given-names></name><name><surname>Campo</surname><given-names>G.</given-names></name><name><surname>Gallone</surname><given-names>G.</given-names></name><name><surname>Verardi</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Reduced rate of hospital admissions for ACS during Covid-19 outbreak in northern Italy</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMc2009166</pub-id><?supplied-pmid 32343497?><pub-id pub-id-type="pmid">32343497</pub-id></element-citation></ref><ref id="B77-jcm-09-01683"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>C.C.F.</given-names></name><name><surname>Cheung</surname><given-names>K.S.</given-names></name><name><surname>Lam</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>A.</given-names></name><name><surname>Yung</surname><given-names>A.</given-names></name><name><surname>Sze</surname><given-names>M.</given-names></name><name><surname>Lam</surname><given-names>Y.M.</given-names></name><name><surname>Chan</surname><given-names>C.</given-names></name><name><surname>Tsang</surname><given-names>T.C.</given-names></name><name><surname>Tsui</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction care in Hong Kong, China</article-title><source>Circ. Cardiovasc. Qual. Outcomes</source><year>2020</year><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.120.006631</pub-id><?supplied-pmid 32182131?><pub-id pub-id-type="pmid">32182131</pub-id></element-citation></ref><ref id="B78-jcm-09-01683"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanini</surname><given-names>G.G.</given-names></name><name><surname>Azzolini</surname><given-names>E.</given-names></name><name><surname>Condorelli</surname><given-names>G.</given-names></name></person-group><article-title>Critical organizational issues for cardiologists in the COVID-19 outbreak: A frontline experience from Milan, Italy</article-title><source>Circulation</source><year>2020</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047070</pub-id><?supplied-pmid 32207994?><pub-id pub-id-type="pmid">32207994</pub-id></element-citation></ref><ref id="B79-jcm-09-01683"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagai</surname><given-names>A.</given-names></name><name><surname>Jollis</surname><given-names>J.G.</given-names></name><name><surname>Dauerman</surname><given-names>H.L.</given-names></name><name><surname>Andrew Peng</surname><given-names>S.</given-names></name><name><surname>Rokos</surname><given-names>I.C.</given-names></name><name><surname>Bates</surname><given-names>E.R.</given-names></name><name><surname>French</surname><given-names>W.J.</given-names></name><name><surname>Granger</surname><given-names>C.B.</given-names></name><name><surname>Roe</surname><given-names>M.T.</given-names></name></person-group><article-title>Emergency department bypass for ST-segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: A report from the American heart association mission: Lifeline program</article-title><source>Circulation</source><year>2013</year><volume>128</volume><fpage>352</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.002339</pub-id><?supplied-pmid 23788525?><pub-id pub-id-type="pmid">23788525</pub-id></element-citation></ref><ref id="B80-jcm-09-01683"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weaver</surname><given-names>W.D.</given-names></name><name><surname>Simes</surname><given-names>R.J.</given-names></name><name><surname>Betriu</surname><given-names>A.</given-names></name><name><surname>Grines</surname><given-names>C.L.</given-names></name><name><surname>Zijlstra</surname><given-names>F.</given-names></name><name><surname>Garcia</surname><given-names>E.</given-names></name><name><surname>Grinfeld</surname><given-names>L.</given-names></name><name><surname>Gibbons</surname><given-names>R.J.</given-names></name><name><surname>Ribeiro</surname><given-names>E.E.</given-names></name><name><surname>DeWood</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review</article-title><source>J. Am. Med. Assoc.</source><year>1997</year><volume>278</volume><fpage>2093</fpage><lpage>2098</lpage><pub-id pub-id-type="doi">10.1001/jama.1997.03550230069040</pub-id></element-citation></ref><ref id="B81-jcm-09-01683"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boersma</surname><given-names>E.</given-names></name></person-group><article-title>Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients</article-title><source>Eur. Heart J.</source><year>2006</year><pub-id pub-id-type="doi">10.1093/eurheartj/ehi810</pub-id></element-citation></ref><ref id="B82-jcm-09-01683"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>Z.C.</given-names></name><name><surname>Zhu</surname><given-names>H.D.</given-names></name><name><surname>Yan</surname><given-names>X.W.</given-names></name><name><surname>Chai</surname><given-names>W.Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>Recommendations from the peking union medical college hospital for the management of acute myocardial infarction during the COVID-19 outbreak</article-title><source>Eur. Heart J.</source><year>2020</year><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa258</pub-id></element-citation></ref><ref id="B83-jcm-09-01683"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Pan</surname><given-names>L.</given-names></name></person-group><article-title>How to balance acute myocardial infarction and COVID-19: The protocols from Sichuan Provincial People&#x02019;s Hospital</article-title><source>Intensive Care Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s00134-020-05993-9</pub-id></element-citation></ref><ref id="B84-jcm-09-01683"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>M.J.</given-names></name><name><surname>Cohen</surname><given-names>M.G.</given-names></name><name><surname>Bavry</surname><given-names>A.A.</given-names></name><name><surname>Kumbhani</surname><given-names>D.J.</given-names></name></person-group><article-title>Reperfusion of STEMI in the COVID-19 Era&#x02014;Business as usual?</article-title><source>Circulation</source><year>2020</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047122</pub-id></element-citation></ref><ref id="B85-jcm-09-01683"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanini</surname><given-names>G.G.</given-names></name><name><surname>Montorfano</surname><given-names>M.</given-names></name><name><surname>Trabattoni</surname><given-names>D.</given-names></name><name><surname>Andreini</surname><given-names>D.</given-names></name><name><surname>Ferrante</surname><given-names>G.</given-names></name><name><surname>Ancona</surname><given-names>M.</given-names></name><name><surname>Metra</surname><given-names>M.</given-names></name><name><surname>Curello</surname><given-names>S.</given-names></name><name><surname>Maffeo</surname><given-names>D.</given-names></name><name><surname>Pero</surname><given-names>G.</given-names></name><etal/></person-group><article-title>ST-elevation myocardial infarction in patients with COVID-19: Clinical and angiographic outcomes</article-title><source>Circulation</source><year>2020</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047525</pub-id><?supplied-pmid 32352306?><pub-id pub-id-type="pmid">32352306</pub-id></element-citation></ref><ref id="B86-jcm-09-01683"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>F.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>Y.</given-names></name></person-group><article-title>Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin</article-title><source>Eur. Heart J.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa190</pub-id></element-citation></ref><ref id="B87-jcm-09-01683"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inciardi</surname><given-names>R.M.</given-names></name><name><surname>Lupi</surname><given-names>L.</given-names></name><name><surname>Zaccone</surname><given-names>G.</given-names></name><name><surname>Italia</surname><given-names>L.</given-names></name><name><surname>Raffo</surname><given-names>M.</given-names></name><name><surname>Tomasoni</surname><given-names>D.</given-names></name><name><surname>Cani</surname><given-names>D.S.</given-names></name><name><surname>Cerini</surname><given-names>M.</given-names></name><name><surname>Farina</surname><given-names>D.</given-names></name><name><surname>Gavazzi</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)</article-title><source>JAMA Cardiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1096</pub-id><?supplied-pmid 32219357?><pub-id pub-id-type="pmid">32219357</pub-id></element-citation></ref><ref id="B88-jcm-09-01683"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangalore</surname><given-names>S.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Slotwiner</surname><given-names>A.</given-names></name><name><surname>Yatskar</surname><given-names>L.</given-names></name><name><surname>Harari</surname><given-names>R.</given-names></name><name><surname>Shah</surname><given-names>B.</given-names></name><name><surname>Ibrahim</surname><given-names>H.</given-names></name><name><surname>Friedman</surname><given-names>G.H.</given-names></name><name><surname>Thompson</surname><given-names>C.</given-names></name><name><surname>Alviar</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>ST-segment elevation in patients with covid-19&#x02014;A case series</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMc2009020</pub-id><?supplied-pmid 32302081?><pub-id pub-id-type="pmid">32302081</pub-id></element-citation></ref><ref id="B89-jcm-09-01683"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmud</surname><given-names>E.</given-names></name><name><surname>Dauerman</surname><given-names>H.L.</given-names></name><name><surname>Welt</surname><given-names>F.G.</given-names></name><name><surname>Messenger</surname><given-names>J.C.</given-names></name><name><surname>Rao</surname><given-names>S.V.</given-names></name><name><surname>Grines</surname><given-names>C.</given-names></name><name><surname>Mattu</surname><given-names>A.</given-names></name><name><surname>Kirtane</surname><given-names>A.J.</given-names></name><name><surname>Jauhar</surname><given-names>R.</given-names></name><name><surname>Meraj</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Management of acute myocardial infarction during the COVID-19 pandemic</article-title><source>J. Am. Coll. Cardiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jacc.2020.04.039</pub-id><?supplied-pmid 32330544?><pub-id pub-id-type="pmid">32330544</pub-id></element-citation></ref><ref id="B90-jcm-09-01683"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>A.K.</given-names></name></person-group><article-title>Temporary emergency guidance to STEMI systems of care during the COVID-19 pandemic: AHA&#x02019;s mission: Lifeline running title: STEMI systems of care during the COVID-19 pandemic</article-title><source>Circulation</source><year>2020</year><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.048180</pub-id></element-citation></ref><ref id="B91-jcm-09-01683"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antman</surname><given-names>E.M.</given-names></name><name><surname>Anbe</surname><given-names>D.T.</given-names></name><name><surname>Armstrong</surname><given-names>P.W.</given-names></name><name><surname>Bates</surname><given-names>E.R.</given-names></name><name><surname>Green</surname><given-names>L.A.</given-names></name><name><surname>Hand</surname><given-names>M.</given-names></name><name><surname>Hochman</surname><given-names>J.S.</given-names></name><name><surname>Krumholz</surname><given-names>H.M.</given-names></name><name><surname>Kushner</surname><given-names>F.G.</given-names></name><name><surname>Lamas</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction&#x02014;Executive summary: A report of the American College of cardiology/American heart association task force on practice guidelines writing committee to revise the 199</article-title><source>Can. J. Cardiol.</source><year>2004</year><volume>20</volume><fpage>977</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2004.07.002</pub-id><pub-id pub-id-type="pmid">15332148</pub-id></element-citation></ref><ref id="B92-jcm-09-01683"><label>92.</label><element-citation publication-type="web"><article-title>SCAI and CAIC Announce the Formation of the North American COVID-19 ST-Segment Elevation Myocardial Infarction Registry (NACMI)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.invasivecardiology.com/news/scai-and-caic-announce-formation-north-american-covid-19-st-segment-elevation-myocardial-infarction-registry-nacmi">https://www.invasivecardiology.com/news/scai-and-caic-announce-formation-north-american-covid-19-st-segment-elevation-myocardial-infarction-registry-nacmi</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-04-16">(accessed on 16 April 2020)</date-in-citation></element-citation></ref><ref id="B93-jcm-09-01683"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welt</surname><given-names>F.G.P.</given-names></name><name><surname>Shah</surname><given-names>P.B.</given-names></name><name><surname>Aronow</surname><given-names>H.D.</given-names></name><name><surname>Bortnick</surname><given-names>A.E.</given-names></name><name><surname>Henry</surname><given-names>T.D.</given-names></name><name><surname>Sherwood</surname><given-names>M.W.</given-names></name><name><surname>Young</surname><given-names>M.N.</given-names></name><name><surname>Davidson</surname><given-names>L.J.</given-names></name><name><surname>Kadavath</surname><given-names>S.</given-names></name><name><surname>Mahmud</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: From the ACC&#x02019;s interventional council and SCAI</article-title><source>J. Am. Coll. Cardiol.</source><year>2020</year><volume>75</volume><fpage>2372</fpage><lpage>2375</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.03.021</pub-id><pub-id pub-id-type="pmid">32199938</pub-id></element-citation></ref><ref id="B94-jcm-09-01683"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>D.A.</given-names></name><name><surname>Sathananthan</surname><given-names>J.</given-names></name><name><surname>Gin</surname><given-names>K.</given-names></name><name><surname>Mansour</surname><given-names>S.</given-names></name><name><surname>Ly</surname><given-names>H.Q.</given-names></name><name><surname>Quraishi</surname><given-names>A.-R.</given-names></name><name><surname>Lavoie</surname><given-names>A.</given-names></name><name><surname>Lutchmedial</surname><given-names>S.</given-names></name><name><surname>Nosair</surname><given-names>M.</given-names></name><name><surname>Bagai</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Precautions and procedures for coronary and structural cardiac interventions during the COVID-19 pandemic: Guidance from Canadian association of interventional cardiology</article-title><source>Can. J. Cardiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cjca.2020.03.027</pub-id></element-citation></ref><ref id="B95-jcm-09-01683"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szerlip</surname><given-names>M.</given-names></name><name><surname>Anwaruddin</surname><given-names>S.</given-names></name><name><surname>Aronow</surname><given-names>H.D.</given-names></name><name><surname>Cohen</surname><given-names>M.G.</given-names></name><name><surname>Daniels</surname><given-names>M.J.</given-names></name><name><surname>Dehghani</surname><given-names>P.</given-names></name><name><surname>Drachman</surname><given-names>D.E.</given-names></name><name><surname>Elmariah</surname><given-names>S.</given-names></name><name><surname>Feldman</surname><given-names>D.N.</given-names></name><name><surname>Garcia</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Considerations for cardiac catheterization laboratory procedures during the COVID-19 pandemic perspectives from the Society for Cardiovascular Angiography and Interventions Emerging Leader Mentorship (SCAI ELM) members and graduates</article-title><source>Catheter. Cardiovasc. Interv.</source><year>2020</year><pub-id pub-id-type="doi">10.1002/ccd.28887</pub-id></element-citation></ref><ref id="B96-jcm-09-01683"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiavone</surname><given-names>M.</given-names></name><name><surname>Forleo</surname><given-names>G.B.</given-names></name><name><surname>Mitacchione</surname><given-names>G.</given-names></name><name><surname>Gasperetti</surname><given-names>A.</given-names></name><name><surname>Viecca</surname><given-names>M.</given-names></name><name><surname>Tondo</surname><given-names>C.</given-names></name></person-group><article-title>Journal Pre-proof Quis custodiet ipsos custodes: Are we taking care of healthcare workers in the Italian Covid-19 outbreak?</article-title><source>J. Hosp. Infect.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jhin.2020.04.045</pub-id><?supplied-pmid 32387745?><pub-id pub-id-type="pmid">32387745</pub-id></element-citation></ref><ref id="B97-jcm-09-01683"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Cheng</surname><given-names>V.C.C.</given-names></name><name><surname>Hung</surname><given-names>I.F.N.</given-names></name><name><surname>Wong</surname><given-names>M.M.L.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Chan</surname><given-names>K.S.</given-names></name><name><surname>Kao</surname><given-names>R.Y.T.</given-names></name><name><surname>Poon</surname><given-names>L.L.M.</given-names></name><name><surname>Wong</surname><given-names>C.L.P.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings</article-title><source>Thorax</source><year>2004</year><pub-id pub-id-type="doi">10.1136/thorax.2003.012658</pub-id><?supplied-pmid 14985565?><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="B98-jcm-09-01683"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>U.J.</given-names></name><name><surname>Won</surname><given-names>E.J.</given-names></name><name><surname>Kee</surname><given-names>S.J.</given-names></name><name><surname>Jung</surname><given-names>S.I.</given-names></name><name><surname>Jang</surname><given-names>H.C.</given-names></name></person-group><article-title>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-a for Middle East respiratory syndrome</article-title><source>Antivir. Ther.</source><year>2016</year><volume>21</volume><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.3851/IMP3002</pub-id><?supplied-pmid 26492219?><pub-id pub-id-type="pmid">26492219</pub-id></element-citation></ref><ref id="B99-jcm-09-01683"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Ruan</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>B.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2001282</pub-id><?supplied-pmid 32187464?><pub-id pub-id-type="pmid">32187464</pub-id></element-citation></ref><ref id="B100-jcm-09-01683"><label>100.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Duangchaemkarn</surname><given-names>K.</given-names></name><name><surname>Reisfeld</surname><given-names>B.</given-names></name><name><surname>Lohitnavy</surname><given-names>M.</given-names></name></person-group><article-title>A pharmacokinetic model of lopinavir in combination with ritonavir in human</article-title><source>Proceedings of the 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society</source><conf-loc>Chicago, IL, USA</conf-loc><conf-date>26&#x02013;30 August 2014</conf-date><fpage>5699</fpage><lpage>5702</lpage></element-citation></ref><ref id="B101-jcm-09-01683"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driggin</surname><given-names>E.</given-names></name><name><surname>Madhavan</surname><given-names>M.V.</given-names></name><name><surname>Bikdeli</surname><given-names>B.</given-names></name><name><surname>Chuich</surname><given-names>T.</given-names></name><name><surname>Laracy</surname><given-names>J.</given-names></name><name><surname>Bondi-Zoccai</surname><given-names>G.</given-names></name><name><surname>Brown</surname><given-names>T.S.</given-names></name><name><surname>Der Nigoghossian</surname><given-names>C.</given-names></name><name><surname>Zidar</surname><given-names>D.A.</given-names></name><name><surname>Haythe</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic</article-title><source>J. Am. Coll. Cardiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jacc.2020.03.031</pub-id></element-citation></ref><ref id="B102-jcm-09-01683"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>P.</given-names></name></person-group><article-title>Non-steroidal anti-inflammatory drugs and covid-19</article-title><source>BMJ</source><year>2020</year><volume>368</volume><fpage>m1185</fpage><pub-id pub-id-type="doi">10.1136/bmj.m1185</pub-id><pub-id pub-id-type="pmid">32220865</pub-id></element-citation></ref><ref id="B103-jcm-09-01683"><label>103.</label><element-citation publication-type="web"><article-title>The Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Patients with COVID-19</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19">https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-18">(accessed on 18 May 2020)</date-in-citation></element-citation></ref><ref id="B104-jcm-09-01683"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Somer</surname><given-names>M.</given-names></name><name><surname>Kallio</surname><given-names>J.</given-names></name><name><surname>Pesonen</surname><given-names>U.</given-names></name><name><surname>Pyykk&#x000f6;</surname><given-names>K.</given-names></name><name><surname>Huupponen</surname><given-names>R.</given-names></name><name><surname>Scheinin</surname><given-names>M.</given-names></name></person-group><article-title>Influence of hydroxychloroquine on the bioavailability of oral metoprolol</article-title><source>Br. J. Clin. Pharmacol.</source><year>2000</year><pub-id pub-id-type="doi">10.1046/j.1365-2125.2000.00197.x</pub-id></element-citation></ref><ref id="B105-jcm-09-01683"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capel</surname><given-names>R.A.</given-names></name><name><surname>Herring</surname><given-names>N.</given-names></name><name><surname>Kalla</surname><given-names>M.</given-names></name><name><surname>Yavari</surname><given-names>A.</given-names></name><name><surname>Mirams</surname><given-names>G.R.</given-names></name><name><surname>Douglas</surname><given-names>G.</given-names></name><name><surname>Bub</surname><given-names>G.</given-names></name><name><surname>Channon</surname><given-names>K.</given-names></name><name><surname>Paterson</surname><given-names>D.J.</given-names></name><name><surname>Terrar</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential</article-title><source>Heart Rhythm</source><year>2015</year><pub-id pub-id-type="doi">10.1016/j.hrthm.2015.05.027</pub-id></element-citation></ref><ref id="B106-jcm-09-01683"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franzosi</surname><given-names>M.G.</given-names></name></person-group><article-title>Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials</article-title><source>Circulation</source><year>1998</year><pub-id pub-id-type="doi">10.1161/01.CIR.97.22.2202</pub-id></element-citation></ref><ref id="B107-jcm-09-01683"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaduganathan</surname><given-names>M.</given-names></name><name><surname>Vardeny</surname><given-names>O.</given-names></name><name><surname>Michel</surname><given-names>T.</given-names></name><name><surname>McMurray</surname><given-names>J.J.V.</given-names></name><name><surname>Pfeffer</surname><given-names>M.A.</given-names></name><name><surname>Solomon</surname><given-names>S.D.</given-names></name></person-group><article-title>Renin&#x02013;angiotensin&#x02013;aldosterone system inhibitors in patients with covid-19</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>1653</fpage><lpage>1659</lpage><pub-id pub-id-type="doi">10.1056/NEJMsr2005760</pub-id><pub-id pub-id-type="pmid">32227760</pub-id></element-citation></ref><ref id="B108-jcm-09-01683"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>J.M.</given-names></name><name><surname>Monogue</surname><given-names>M.L.</given-names></name><name><surname>Jodlowski</surname><given-names>T.Z.</given-names></name><name><surname>Cutrell</surname><given-names>J.B.</given-names></name></person-group><article-title>Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review</article-title><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.6019</pub-id></element-citation></ref><ref id="B109-jcm-09-01683"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>D.</given-names></name><name><surname>Van Ermen</surname><given-names>A.</given-names></name></person-group><article-title>Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin</article-title><source>Am. J. Health Pharm.</source><year>2017</year><volume>74</volume><fpage>888</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.2146/ajhp160730</pub-id><?supplied-pmid 28596225?><pub-id pub-id-type="pmid">28596225</pub-id></element-citation></ref><ref id="B110-jcm-09-01683"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puglisi</surname><given-names>G.M.</given-names></name><name><surname>Smith</surname><given-names>S.M.</given-names></name><name><surname>Jankovich</surname><given-names>R.D.</given-names></name><name><surname>Ashby</surname><given-names>C.R.</given-names></name><name><surname>Jodlowski</surname><given-names>T.Z.</given-names></name></person-group><article-title>Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: A case report</article-title><source>J. Clin. Pharmacol.</source><year>2017</year><volume>42</volume><fpage>115</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1111/jcpt.12475</pub-id></element-citation></ref><ref id="B111-jcm-09-01683"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N.</given-names></name><name><surname>Bai</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name></person-group><article-title>Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy</article-title><source>J. Thromb. Haemost.</source><year>2020</year><pub-id pub-id-type="doi">10.1111/jth.14817</pub-id><?supplied-pmid 32220112?><pub-id pub-id-type="pmid">32220112</pub-id></element-citation></ref><ref id="B112-jcm-09-01683"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valgimigli</surname><given-names>M.</given-names></name><name><surname>Bueno</surname><given-names>H.</given-names></name><name><surname>Byrne</surname><given-names>R.A.</given-names></name><name><surname>Collet</surname><given-names>J.P.</given-names></name><name><surname>Costa</surname><given-names>F.</given-names></name><name><surname>Jeppsson</surname><given-names>A.</given-names></name><name><surname>J&#x000fc;ni</surname><given-names>P.</given-names></name><name><surname>Kastrati</surname><given-names>A.</given-names></name><name><surname>Kolh</surname><given-names>P.</given-names></name><name><surname>Mauri</surname><given-names>L.</given-names></name><etal/></person-group><article-title>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</article-title><source>Eur. J. Cardio-Thorac. Surg.</source><year>2018</year><volume>53</volume><fpage>34</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezx334</pub-id><?supplied-pmid 29045581?><pub-id pub-id-type="pmid">29045581</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="jcm-09-01683-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>&#x0201c;Covid-19 related delays&#x0201d; in treating ST-elevation myocardial infarction (STEMI) patients. Adapted from Ibanez et al., 2017 European Society of Cardiology Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation [<xref rid="B70-jcm-09-01683" ref-type="bibr">70</xref>]. <bold>Abbreviations:</bold> Covid-19: coronavirus disease; EMS: emergency medical services; FMC: first medical contact; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction.</p></caption><graphic xlink:href="jcm-09-01683-g001"/></fig><table-wrap id="jcm-09-01683-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">jcm-09-01683-t001_Table 1</object-id><label>Table 1</label><caption><p>Mechanisms of myocardial injury. Adapted from Thygesen et al. Fourth universal definition of myocardial infarction (2018) [<xref rid="B13-jcm-09-01683" ref-type="bibr">13</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Myocardial Injury</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Related to Primary Acute Myocardial Ischemia</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Related to Oxygen Supply/Demand Imbalance</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other Causes</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Plaque rupture&#x02014;erosion with occlusive thrombosis<break/>Plaque rupture&#x02014;erosion with non-occlusive thrombosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Reduced myocardial perfusion</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Cardiac conditions</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coronary artery spasm<break/>Microvascular dysfunction<break/>Coronary embolism<break/>Coronary artery dissection<break/>Sustained bradyarrhythmia<break/>Hypotension or shock<break/>Respiratory failure with hypoxaemia<break/>Severe anaemia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heart failure<break/>Myocarditis<break/>Cardiomyopathy (any type)<break/>Takotsubo syndrome<break/>Coronary revascularization procedure<break/>Cardiac procedure other than revascularization<break/>Catheter ablation<break/>Defibrillator shocks<break/>Cardiac contusion</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Increased myocardial oxygen demand</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Systemic conditions</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sustained tachyarrhythmia<break/>Severe hypertension with or without left ventricular hypertrophy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sepsis, infectious disease<break/>Chronic kidney disease<break/>Stroke, subarachnoid hemorrhage<break/>Pulmonary embolism, pulmonary hypertension<break/>Infiltrative diseases, e.g., amyloidosis, sarcoidosis<break/>Chemotherapeutic agents<break/>Critically ill patients<break/>Strenuous exercise</td></tr></tbody></table></table-wrap><table-wrap id="jcm-09-01683-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">jcm-09-01683-t002_Table 2</object-id><label>Table 2</label><caption><p>Acute coronary syndromes and other acute respiratory infection&#x02014;main studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study, Year, Journal</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Infection</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Population and Timeline</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Myocardial Infarction Diagnosis</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cases with Myocardial Infarction and Respiratory Infectious Disease</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Smeeth et al., 2004, New England Journal of Medicine</bold> [<xref rid="B42-jcm-09-01683" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Systemic respiratory tract infection (pneumonia, acute bronchitis, chest infections, and influenza)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI diagnosed 91 days after infection exposure </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UK GPRD data (1495 cases were excluded because the date of the MI was uncertain)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 3254<break/>Respiratory infectious disease: <italic>n</italic> = 20,921</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Kwong et al., 2018, New England Journal of Medicine</bold> [<xref rid="B43-jcm-09-01683" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A/B, RSV, adenovirus, CoV, enterovirus (including rhinovirus), HPIV, and HMPV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Admission for MI within 7 days after laboratory confirmation of influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICD-10 diagnostic code</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 364<break/>Respiratory infectious disease: <italic>n</italic> = 19,045</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Warren-Gash et al., 2013, British Medical Journal</bold> [<xref rid="B44-jcm-09-01683" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A H1N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Respiratory tract infection developed within one month before admission for MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cTn elevation with ischemic symptoms or typical ECG changes, or by angiographic findings</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 134<break/>Respiratory infectious disease: <italic>n</italic> = 13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Violi et al., 2017, Clinical infectious diseases</bold> [<xref rid="B45-jcm-09-01683" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI during hospitalization for CAP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Third universal definition of AMI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 89<break/>(NSTEMI = 78 STEMI = 11)<break/>Respiratory infectious disease: <italic>n</italic> = 1182</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Musher et al., 2007, Clinical infectious diseases</bold> [<xref rid="B46-jcm-09-01683" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumococcal pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI diagnosed at hospital admission for pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New ECG abnormalities (i.e., ST segment elevation or depression or Q waves) accompanied by cTn elevation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 12<break/>(NSTEMI = 9 STEMI = 3)<break/>Respiratory infectious disease: <italic>n</italic> = 170</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Corrales-Medina et al., 2015, Journal of American Medical Association</bold> [<xref rid="B47-jcm-09-01683" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI and fatal coronary heart disease over 10 years after pneumonia hospitalization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two algorithms based on symptoms, cardiac enzymes, and electrocardiographic evidence</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 247<break/>Respiratory infectious disease: <italic>n</italic> = 1271</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Vejpongsa et al., 2019, The American Journal of Medicine</bold> [<xref rid="B48-jcm-09-01683" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute influenza and other viral respiratory infections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute influenza and other viral infections in hospital admission for MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICD-9 diagnostic code</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 1,884,985<break/>Respiratory infectious disease: <italic>n</italic> = 21,370<break/>(Acute influenza = 9885 Other = 11,485) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Caussin et al., 2015, International Journal of Cardiology</bold> [<xref rid="B49-jcm-09-01683" ref-type="bibr">49</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wide spectrum of respiratory tract infection (flu-like illness with fever and sore throat), pneumonia or bronchitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Possible exposure to respiratory infection within 35 days prior to admission for MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiographically confirmed MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 578<break/>Respiratory infectious disease: <italic>n</italic> = 123</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Ruane et al., 2017, Internal Medicine Journal,</bold> [<xref rid="B50-jcm-09-01683" ref-type="bibr">50</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Association between STEMI and influenza epidemic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Angiographically confirmed STEMI (&#x02264;24 h) with at least &#x02265;50% coronary stenosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 11,987<break/>Respiratory infectious disease: <italic>n</italic> = NA (ERR 8.9)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Peiris et al, 2003, The Lancet</bold> [<xref rid="B51-jcm-09-01683" ref-type="bibr">51</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deaths for MI in hospitalized patients with SARS </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 2<break/>Respiratory infectious disease: <italic>n</italic> = 75</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Chong et al., 2004, Archives of Pathology and Laboratory Medicine</bold> [<xref rid="B52-jcm-09-01683" ref-type="bibr">52</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI in post-mortem examinations for confirmed SARS infections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Post-mortem</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI: <italic>n</italic> = 2<break/>Respiratory infectious disease: <italic>n</italic> = 8</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>No data available</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Abbreviations:</bold> CAP: community acquired pneumonia; CoV: coronavirus; cTn: cardiac troponin; GPRD: General Practice Research Database; ERR: excess relative risk; HMPV: human metapneumovirus; HPIV: human parainfluenza virus; ICD: international classification of diseases; MERS: Middle East respiratory syndrome; MI: myocardial infarction; NA: not available, NSTEMI: myocardial infarction without ST-segment elevation; RSV: respiratory syncytial virus; SARS-CoV: severe acute respiratory syndrome coronavirus; STEMI: ST-segment elevation myocardial infarction; UK: United Kingdom.</p></fn></table-wrap-foot></table-wrap><table-wrap id="jcm-09-01683-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">jcm-09-01683-t003_Table 3</object-id><label>Table 3</label><caption><p>Myocardial injury and ACS in patients with Covid-19&#x02014;main studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study, Year, Journal.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Population</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evaluation and Timeline</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cases with Myocardial Injury</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Suspected ACS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">in Hospital Mortality</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Huang et al., 2020, The Lancet</bold> [<xref rid="B5-jcm-09-01683" ref-type="bibr">5</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 41<break/>ICU = 13<break/>Non-ICU = 28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myocardial injury = increased cardiac biomarkers or new ECG&#x02014;echo abnormalities during hospitalization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 5 (12%)<break/>ICU = 4 (31%)<break/>Non-ICU = 1 (4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 6 (15%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Wang et al., 2020, Journal of American Medical Association</bold> [<xref rid="B1-jcm-09-01683" ref-type="bibr">1</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 138<break/>ICU = 36<break/>Non-ICU = 102</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myocardial injury = increased cardiac biomarkers or new ECG&#x02014;echo abnormalities during hospitalization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 10 (7.2%)<break/>ICU = 8 (22.2%)<break/>Non-ICU = 2 (2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 6 (43%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Zhou et al., 2020, The Lancet</bold> [<xref rid="B66-jcm-09-01683" ref-type="bibr">66</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 191<break/>Non-survivor = 54<break/>Survivor = 137</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myocardial injury = increased cardiac biomarkers or new ECG&#x02014;echo abnormalities during hospitalization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 33 (17%)<break/>Non-survivor = 32 (59%)<break/>Survivor = 1 (1%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">First autopsy performed = findings were consistent with AMI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 54 (28.3%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Shi et al., 2020, Journal of American Medical Association: Cardiology</bold> [<xref rid="B6-jcm-09-01683" ref-type="bibr">6</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 416</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Myocardial injury = increased cardiac biomarkers regardless of new ECG&#x02014;echo abnormalities during hospitalization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 82 (19.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ECG features consistent with myocardial ischemia&#x02014;NSTEMI: <italic>n</italic> = 14 (3.36%) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>n</italic> = 57 (13.7%)<break/>With cardiac injury = 42 (51.2%)<break/>Without cardiac injury = 15 (4.5%)</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Abbreviations:</bold> ACS: acute coronary syndromes; AMI: acute myocardial infarction; ECG: electrocardiogram; ICU: intensive care unit; NA: not available; NSTEMI: myocardial infarction without ST-segment elevation; STEMI: ST-segment elevation myocardial infarction.</p></fn></table-wrap-foot></table-wrap><table-wrap id="jcm-09-01683-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">jcm-09-01683-t004_Table 4</object-id><label>Table 4</label><caption><p>Drug treatment of acute coronary syndromes and coronary artery disease&#x02014;evidence and potential interactions with drugs used to treat SARS-CoV-2 infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Potential Interactions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evidence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Notes</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>P2Y12 inhibitor</underline>:<list list-type="simple"><list-item><label>-</label><p>Clopidogrel</p></list-item><list-item><label>-</label><p>Ticagrelor</p></list-item><list-item><label>-</label><p>Prasugrel</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lopinavir&#x02013;Ritonavir</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">When coadministered with lopinavir&#x02013;ritonavir, diminished effect of clopidogrel, increased effect of ticagrelor [<xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Consider using prasugrel if no contraindications [<xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>].<break/>Contraindications to prasugrel: previous intracranial hemorrhage, previous ischemic stroke or TIA, or ongoing bleeds; prasugrel is not recommended for patients &#x0003e;75 years of age or with a body weight &#x0003c;60 kg; or in NSTE-ACS if coronary anatomy is not known [<xref rid="B112-jcm-09-01683" ref-type="bibr">112</xref>].<break/>Contraindications for ticagrelor: previous intracranial hemorrhage or ongoing bleeds [<xref rid="B112-jcm-09-01683" ref-type="bibr">112</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<underline>Aspirin</underline>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lack of evidence on discontinuation of aspirin in Covid-19 patients. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low-dose aspirin can be assumed to be safe as antiplatelet drug in Covid-19 patients [<xref rid="B103-jcm-09-01683" ref-type="bibr">103</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>Statins</underline>:<list list-type="simple"><list-item><label>-</label><p>Atorvastatin</p></list-item><list-item><label>-</label><p>Rosuvastatin</p></list-item><list-item><label>-</label><p>Lovastatin</p></list-item><list-item><label>-</label><p>Simvastatin</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lopinavir&#x02013;Ritonavir</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">When coadministered with lopinavir&#x02013;ritonavir, increased effect of atorvastatin and rosuvastatin [<xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>]. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Start at lowest possible dose of rosuvastatin and atorvastatin and titrate, otherwise use pravastatin [<xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><underline>Beta-blockers</underline>:<list list-type="simple"><list-item><label>-</label><p>Metoprolol</p></list-item><list-item><label>-</label><p>Carvedilol</p></list-item><list-item><label>-</label><p>Propranolol</p></list-item><list-item><label>-</label><p>Labetalol</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chloroquine&#x02013;Hydroxychloroquine Fingolimod</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hydroxychloroquine has a potential role in reducing heart rate and may increase effect of beta-blockers [<xref rid="B105-jcm-09-01683" ref-type="bibr">105</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">When coadministered with chloroquine or hydroxychloroquine, beta-blockers dose reduction may be required [<xref rid="B105-jcm-09-01683" ref-type="bibr">105</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACEi/ARbs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No human evidence establishing a link between the use of these medications with an increased risk of Covid-19 acquisition or illness severity [<xref rid="B108-jcm-09-01683" ref-type="bibr">108</xref>].</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abrupt withdrawal in high-risk patients, especially those who have heart failure or have had MI, may result in clinical instability and adverse outcomes [<xref rid="B107-jcm-09-01683" ref-type="bibr">107</xref>,<xref rid="B108-jcm-09-01683" ref-type="bibr">108</xref>].</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heparin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">First evidences showed decreased mortality in severe Covid-19 patients with coagulopathy [<xref rid="B111-jcm-09-01683" ref-type="bibr">111</xref>]. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Given the interactions between some antiviral drugs and OACs, low molecular weight heparins, or unfractionated heparin should be preferred over OACs [<xref rid="B101-jcm-09-01683" ref-type="bibr">101</xref>].</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Abbreviations</bold>: ACEi: ACE inhibitors; ARBs: angiotensin receptor blockers; Covid-19: coronavirus disease; MI: myocardial infarction; NSAIDS: nonsteroidal anti-inflammatory drugs; NSTE-ACS: acute coronary syndromes without ST-segment elevation; OACs: oral anticoagulants; TIA: transient ischemic attack.</p></fn></table-wrap-foot></table-wrap></floats-group></article>